Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine by Lockridge, Oksana
Pharmac. Ther. Vol. 47, pp. 35~o0, 1990 0163-7258/90 $0.00 + 0.50 
Printed in Great Britain. All rights reserved © 1990 Pergamon Press plc 
Specialist Subject Editor: W. KALOW 
GENETIC VARIANTS OF HUMAN SERUM 
CHOLINESTERASE INFLUENCE METABOLISM OF 
THE MUSCLE RELAXANT SUCCINYLCHOLINE 
OKSANA LOCKRIDGE 
Pharmacology Department, Medical Science I, M6322, University of Michigan Medical School, 
Ann Arbor, M1 48109-0626, U.S.A. 
Abstract--People with genetic variants of cholinesterase respond abnormally to succinylcholine, experi- 
encing substantial prolongation of muscle paralysis with apnea rather than the usual 2-6 min. The 
structure of usual cholinesterase has been determined including the complete amino acid and nucleotide 
sequence. This has allowed identification of altered amino acids and nucleotides. The variant most 
frequently found in patients who respond abnormally to succinylcholine is atypical cholinesterase, 
which occurs in homozygous form in 1 out of 3500 Caucasians. Atypical cholinesterase has a single 
substitution at nucleotide 209 which changes aspartic acid 70 to glycine. This suggests that Asp 70 is part 
of the anionic site, and that the absence of this negatively charged amino acid explains the reduced affinity 
of atypical cholinesterase for positively charged substrates and inhibitors. The clinical consequence of 
reduced affinity for succinylcholine is that none of the succinylcholine is hydrolyzed in blood and a large 
overdose reaches the nerve-muscle junction where it causes prolonged muscle paralysis. Silent 
cholinesterase has a frame shift mutation at glycine 117 which prematurely terminates protein synthesis 
and yields no active enzyme. The K variant, named in honor of W. Kalow, has threonine in place of 
alanine 539. The K variant is associated with 33% lower activity. All variants arise from a single locus 
as there is only one gene for human cholinesterase (EC 3.1.1.8). Comparison of amino acid sequences of 
esterases and proteases shows that cholinesterase belongs to a new family of serine esterases which is 
different from the serine proteases. 
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1.1. USE OF SUCCINYLCHOLINE LED TO DISCOVERY 
OF ATYPICAL CHOLINESTERASE 
Succinylcholine was introduced for use as a muscle 
relaxant in 1951 because it produced prompt and 
complete paralysis, was followed by rapid recovery, 
and seemed free from toxic side-effects. A problem 
was soon noticed. In some patients the duration 
of action was much longer than expected; muscle 
paralysis could last for hours rather than the usual 
2-6 min. These patients were unable to breathe and 
had to be maintained on mechanical ventilators. 
While the cause of this abnormal response was 
suspected to be an abnormal cholinesterase it was not 
until 1956, when Werner Kalow first described the 
atypical cholinesterase variant, that a biochemical 
basis was provided for the clinical observation. 
Kalow reported that the abnormal response was due 
to an atypical serum cholinesterase whose affinity for 
succinylcholine was so low that it failed to hydrolyze 
any of the injected succinylcholine. Kalow and 
Staron (1957) showed that atypical cholinesterase 
was a heritable trait. Thus, the genetic basis of the 
abnormal response was established, and the field of 
pharmacogenetics was born. 
In the 33 years since the discovery of atypical 
cholinesterase, the basic concepts introduced by 
Kalow remain unchanged and have been strength- 
ened by analysis of several hundred thousand blood 
samples in laboratories throughout the world. It is 
accepted that a person who has atypical cholin- 
esterase will always respond with prolonged apnea 
if he receives a standard dose of succinylcholine. 
The phenotyping procedure introduced by Kalow 
and Genest (1957), which includes determination 
of dibucaine number, is the most widely used 
method today. Kalow's observations that atypical 
cholinesterase is defective in its ability to bind posi- 
tively charged esters and that atypical cholinesterase 
is an inherited trait have been confirmed in many 
laboratories. The interpretation (Kalow and Davies, 
1958) that atypical cholinesterase has an amino acid 
alteration at the anionic binding site is supported by 
recent DNA sequencing results. 
Since the publication of Kalow's book in 1962, 
Pharmacogenetics, Heredity and the Response to 
Drugs, additional genetic variants of cholinesterase 
have been recognized. Population distributions of the 
most readily identifiable variants, the atypical and 
silent, have been done on most continents. More 
drugs have been added to the list of esters hydrolyzed 
by cholinesterase, and more cholinesterase inhibitors 
have been identified. Reviews which focus on clinical 
experience with succinylcholine and correlate pro- 
longed apnea with cholinesterase are by Whittaker 
(1980) and Viby-Mogensen (1983). The review by 
Harris (1980) explains how a small number of genetic 
variants may underlie the continuously graded vari- 
ation in cholinesterase activity. Brown et al. (1981) 
review the cholinesterase variants, succinylcholine 
apnea, clinical applications of activity measurements, 
detection methods for variants, and the biochemical 
properties of cholinesterase. The monograph by 
Whittaker (1986) covers the genetic variants of 
cholinesterase, their biochemical properties, occur- 
rence, ethnic distribution, methods for phenotyping 
genetic variants, and the level of cholinesterase in 
various diseases. The present review focusses on 
new information since Whittaker's monograph. The 
complete amino acid sequence of usual cholinesterase 
has been determined, as well as the location of 
disulfide bonds and carbohydrate chains. The cDNA 
clone of usual cholinesterase has been isolated and 
sequenced. The cholinesterase gene has been isolated 
and mapped and it has been shown that there is only 
one cholinesterase gene. Finally, the nucleotide alter- 
ations in the genes coding for atypical, one type of 
silent, and the K variant of cholinesterase have been 
determined. 
1.2. DEFINITION OF CHOLINESTERASE 
The cholinesterase discussed here is EC 3.1.1.8, 
acylcholine acyhydrolase. Other names are butyryl- 
cholinesterase, pseudocholinesterase, and nonspecific 
cholinesterase. Cholinesterase is distinguished from 
a related enzyme called acetylcholinesterase (EC 
3.1.1.7) or true cholinesterase, by substrate prefer- 
ence, inhibitor specificity, and by antibody recogni- 
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tion (Brimijoin and Hammond, 1988). Human 
plasma and serum are a rich source of cholinesterase, 
whereas human red blood cell membranes are a 
source of acetylcholinesterase. 
2. CLINICAL ASPECTS 
2.1. ROLE OF CHOLINESTERASE IN DETERMINING FATE 
AND ACTION OF SUCCINYLCHOLINE 
Succinylcholine is hydrolyzed by cholinesterase to 
form succinylmonocholine and choline. While the 
diester is a powerful muscle relaxant, the monoester 
has little pharmacologic activity. When succinyl- 
choline is iniected intravenously about 90% of an 
ordinary dose is hydrolyzed by cholinesterase within 
1 min (Kalow, 1962a). Thus the actual dose of suc- 
cinylcholine that reaches the nerve-muscle junction is 
far smaller than the injected dose. At the nerve-end 
plate succinylcholine binds to a receptor with the 
result that the nerve-end plate is depolarized and 
loses sensitivity to the neurotransmitter acetylcholine, 
causing the patient to experience complete muscle 
paralysis. Duration of neuromuscular block can be 
monitored with precision by using an electric nerve 
stimulator (Viby-Mogensen, 1983). 
Recovery from succinylcholine is rapid if the dose 
of succinylcholine that reaches the nerve-end plate is 
low. However, a dose producing an effect normally 
lasting 2 min produces in the absence of hydrolysis 
by cholinesterase an apnea of about 1 hr (Kalow 
and Gunn, 1957). Muscle paralysis prolonged much 
beyond an hour probably represents abnormalities 
or interferences at the neuromuscular end plate unless 
a very large dose of succinylcholine is injected. 
Recovery does not begin until most of the succinyl- 
choline has been hydrolyzed or cleared from blood 
and extracellular fluid. During the period of complete 
paralysis a significant amount of succinylcholine is 
present in blood and extracellular fluid as can be 
inferred from the observation that injection of con- 
centrated cholinesterase at this time, but at no other 
time, shortens the period of apnea (Viby-Mogensen, 
1981b). After the blood and extracellular fluid have 
been cleared of succinylcholine the rate of recovery 
from apnea depends on the concentration of succinyl- 
choline remaining at the nerve-end plate, that is, on 
the number of receptors occupied, and on the rate 
of diffusion of succinylcholine away from the nerve- 
end plate. The importance of extracellular fluid 
as a compartment containing both succinylcholine 
and cholinesterase is supported by measurements of 
volume of distribution. Following intravenous injec- 
tion of purified cholinesterase, the volume of distribu- 
tion was 18% of body weight, or about 13 L for a 
70kg person (Ostergaard et al., 1988). This 13 L 
includes 2.8 L total blood volume and 10.5 L total 
extracellular fluid volume. 
The nerve-end plate is normal in people who have 
atypical cholinesterase as indicated by their normal 
response to decamethonium and D-tubocurarine 
(Kalow, 1962a, b), two neuromuscular blocking 
drugs that have no ester bonds and are not hydro- 
lyzed by cholinesterase. Further evidence supporting 
this point comes from Kalow and Gunn (1957) 
who showed that a plot of log dose succinylcholine 
versus log rain of apnea gave a series of parallel lines 
(Fig. 1). The slope of this line was identical in all 
persons regardless of their cholinesterase genotype or 
level of cholinesterase activity. The constant slope 
indicated that doubling the dose of succinylcholine 
increased the duration of apnea by a factor of 1.5 in 
all cholinesterase genotypes. The constant slope also 
meant that termination of apnea depended on a 
common process such as diffusion of succinylcholine 
away from the nerve-end plate, and that cholin- 
esterase had no effect on the rate of diffusion (Kalow, 
1962b). 
The exaggerated response by people with 
atypical cholinesterase is explained by the inability 
of atypical cholinesterase to hydrolyze succinyl- 
choline. Atypical cholinesterase has a low affinity for 
succinylcholine so that it does not bind succinyl- 
choline when the succinylcholine concentration is in 
the pharmacologic range. In test tube experiments 
where the succinylcholine concentration can be raised 
to saturating levels, atypical cholinesterase hydro- 
lyzes succinylcholine with the same extrapolated 
maximal velocity as usual cholinesterase. The conse- 
quence of atypical cholinesterase's low affinity for 
succinylcholine is that none of the administered drug 
is hydrolyzed in blood. Therefore, the nerve-end plate 
receives a 50-100-fold overdose of succinylcholine 
(Kalow, 1962a, b). 
Cholinesterase has no effect on succinylcholine 
once the drug is at the nerve-end plate. This is 
demonstrated by the fact that injection of concen- 
trated cholinesterase has no pronounced effect on the 
duration of apnea when cholinesterase is adminis- 
tered late, approximately 90 min after a single dose 
of succinylcholine (Viby-Mogensen, 1981b) in a per- 
son with the atypical genotype. The proper time for 
cholinesterase injection can be determined by using a 
nerve stimulator (Viby-Mogensen, 1983). 
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FIG. 1. Logar i thmic plot o f  the relation between dose o f  
succinylcho]ine chloride and durat ion o f  apnea. Data are for  
one person with atypical cholinesterase (AA), one het- 
erozygote (AF), one person with a low level of usual 
cholinesterase (UU), and one with a high level of usual 
cholinesterase (UU). The parallel lines indicate that neither 
the amount of cholinesterase nor the genotype affect the rate 
of recovery from succinylcholine apnea once succinylcholine 
is at the nerve end plate (Kalow and Gunn, 1957). Reprinted 
with the permission of the authors and the copyright holder, 
The American Society for Pharmacology and Experimental 
Therapeutics, Bethesda. 
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Treatment of succinylcholine apnea with commer- 
cially purified, concentrated cholinesterase has been 
extensively tested at the Danish Cholinesterase 
Research Unit, and though this treatment is effective 
it is not recommended for routine use (Viby- 
Mogensen, 1983). One reason is that the injected 
cholinesterase works only if it is administered at 
the right time; given late, it has little or no effect. 
A second reason is its expense. A third reason is the 
risk of infection from a human blood product. 
When nerve stimulation shows presence of a phase 
II block, neostigmine can be used to shorten block. 
Neostigmine can shorten block even though it is 
an anticholinesterase drug, because during phase II 
block its effect is not on cholinesterase. Instead 
neostigmine stimulates the end plate to overcome the 
nondepolarizing, phase II block. If neostigmine is 
given before succinylcholine or while succinylcholine 
is still in blood, it inhibits cholinesterase with the 
result that apnea is prolonged (Viby-Mogensen, 
1983). 
2.2 GENETIC VARIANTS OF CHOLINESTERASE 
Because DNA sequencing has revealed the precise 
location of nucleotide alterations in some of these 
variants, and multiple nucleotide substitutions within 
one variant are likely to be revealed in the near 
future, a more precise nomenclature is introduced 
in Table 1. The descriptive name is followed by the 
affected amino acid, its position in the mature 
protein, and the altered amino acid. Another pro- 
posed modification to the nomenclature is elimina- 
tion of the terms E1 and E2 which refer to two 
cholinesterase loci. As there is only one gene for 
human cholinesterase (located on the long arm of 
chromosome 3 at q21-25), all cholinesterase geno- 
types must arise from this locus. Abbreviations can 
be simplified by calling homozygotes UU, AA, 
SS, FF, KK, J J, and HH. Heterozytes can be abbre- 
viated to show two of these alleles, for example 
UA for usual-atypical. Silent is called Silent-I 
because we anticipate that additional silent variants 
will be identified. The next silent will be called 
Silent-2. In the future some variants may be shown 
to arise from nucleotide alterations in untranslated 
regions, for example in the regulatory regions of 
the gene. These can be designated by nucleotide 
numbers. 
The genetic variant most often found in patients 
who have an abnormal response to succinylcholine is 
atypical cholinesterase, AA. The silent allele was first 
proposed by Liddell et  al. (1962) and confirmed 
by many laboratories (Altland and Goedde, 1970; 
Rubinstein e t  al. ,  1970). Silent cholinesterase has 
0-2% of normal activity. The fluoride variant was 
recognized by Harris and Whittaker (1961) who 
used NaF inhibition to identify the AF phenotype. 
The H, J, and K variants are quantitative variants. 
Despite their reduced activity they are indistinguish- 
able from usual cholinesterase (UU) in UH, U J, 
and UK phenotypes, but are detectable when they 
occur in heterozygote combination with atypical 
cholinesterase (AH, A J, and AK). The H variant has 
been found in two families and is associated with a 
greater than 90% decrease in activity similar to the 
low activity in silent cholinesterase (Whittaker and 
Britten, 1987). The J variant has a frequency of 1 
in 150,000 and is associated with a 66% decrease in 
activity (Garry et  al.,  1976; Evans and Wardell, 1984). 
The K variant has a frequency of 1% and is associ- 
ated with a 33% decrease in activity (Rubinstein et  
al. ,  1978; Whittaker and Britten, 1985). Mildly pro- 
longed apnea can occur in persons with UA or AK 
phenotypes. A longer apnea occurs in persons with 
AF, FS, or AJ phenotypes. The most pronounced 
effect of succinylcholine with the longest duration of 
muscle paralysis occurs in persons with the SS, AA, 
and AS genotypes (Viby-Mogensen, 1983). 
One family in Newfoundland was found to have a 
rare variant recognized by a high percentage inhibi- 
tion by dibucaine (Simpson and Elliott, 1981). The 
TABLE 1. Genetic Variants o f  Cholinesterase 
Trivial Formal name 





(70 Asp ~ Gly) 
Silent-I 
( 117 Gly ---, frameshifl) 
Fluoride 
Quantitative variant J 
Quantitative variant K 
(539 Ala ~ Thr) 






UU CHE Whittaker, 1986 
AA CHE*70G/CHE*70G Kalow and Staron, 1957 
McGuire et al., 1989 
SS CHE*FS117/CHE*FS117 Liddell et al., 1962 
McGuire et al., 1989 
FF Harris and Whittaker, 1961 
JJ Garry et al., 1976 
Evans and Wardell, 1984 
KK CHE*539T/CHE*539T Rubinstein et aL, 1978 
Bartels et aL, 1989 
HH Whittaker and Britten, 1987 
Simpson and EUiott, 1981 
Robson and Harris, 1966 
Neitlich, 1966 
Whittaker, 1986 
Krause et al., 1988 
Formal names follow the rules of the Committee for Human Gene Nomenclature (Shows et al., 1987). 
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proband, who was heterozygous for the Newfound- 
land and atypical alleles, was sensitive to succinyl- 
choline. 
Four families with higher than normal cholin- 
esterase activity have been reported. These persons 
are resistant to succinylcholine. The high cholin- 
esterase activity variant is called Cynthiana after its 
place of origin (Neitlich, 1966; Whittaker, 1986). A 
South African family descended from Dutch and 
German immigrants was found to have twice the 
normal activity (Krause e t  al. ,  1988) and a normal 
number of enzyme molecules. This distinguished the 
South African variant from the Cynthiana because 
the Cynthiana had increased activity accompanied by 
increased amount of cholinesterase protein. 
The C5+ variant has an extra band on electro- 
phoresis and is associated with up to 30% increase in 
activity (Robson and Harris, 1966). The literature has 
claimed that C5 + originates from a second cholin- 
esterase locus, called E2. Recent results from our 
laboratory have shown, however, that there is only 
one gene for cholinesterase. Therefore a second 
cholinesterase locus does not exist. The C5 + band is 
probably an association between cholinesterase and a 
second as yet unidentified protein (Scott and Powers, 
1974). The E2 locus may specify this second, modify- 
ing protein. The C5 + variant is not important to the 
anesthetist as it does not affect response to succinyl- 
choline. 
2.3. ETHNIC DISTRIBUTION OF GENETIC VARIANTS 
Most of the data are for atypical cholinesterase 
because this is the only variant that has reliably 
been identified in both heterozygote and homo- 
zygote forms. Whittaker (1986) presented a compre- 
hensive summary of results for the entire world, 
including maps showing cholinesterase allele frequen- 
cies in various populations. The data below are from 
Whittaker (1986). 
In European populations the average frequency 
of the atypical allele is 0.017 in a total of 36,000 
individuals tested. A frequency of 0.017 means that 1 
out of 3500 people is homozygous atypical. Groups 
that have a much higher frequency are the French in 
Toulouse (0.0299), some Greeks (0.0561) and 
Spaniards in Galicia (0.0279), Basque (0.0312), and 
Valencia (0.0732). A low frequency was found in 
Icelanders; out of 128 Icelanders tested, none had the 
atypical allele. 
The Jews of Iraq and Iran have a high frequency 
of the atypical allele, 0.0473 and 0.0755, out of 1057 
and 159 people tested. This contrasts with Jews from 
Europe, North Africa, Yemen, Lebanon, and Syria 
who have the same gene frequency as the general 
European population. A frequency of 0.0755 means 
that 1 out of every 175 Iranian Jews is homozygous 
atypical, and that approximately 8 out of every 100 
carry the atypical allele. 
The lowest frequency of the atypical allele is in 
Orientals and African Negroes, where many groups 
had zero atypical alleles and where the average 
frequency of 0.0002 calculates to 1 homozygous 
atypical in 25 million people. 
The silent allele is infrequent (0.0003) in European 
populations, where only one out of 10 million is 
homozygous silent. In India the silent allele is rare 
in the general population, although one group, the 
Vysyas of Andhra Pradesh have an exceptionally high 
frequency of 0.112. A high frequency of the silent 
allele (0.1114) was found in Alaskan Eskimos where 
out of 1603 people tested, 28 were homozygous silents 
and 301 were heterozygotes. 
There are few estimates of the frequency of 
the fluoride variant. The gene appears to be rare. 
In European populations where it has been most 
studied, its frequency is 0.0021. 
Approximately 40,000 people have been tested 
for the C5+  variant. It is present in 9% of 
Europeans, 3% of Asians, 5% of Africans and 7% 
of Americans. 
2.4. RELATION BETVCEEN DOSE OF SUCCINYLCHOLINE 
AND DURATION OF APNEA 
Kalow and Gunn (1957) measured duration of 
apnea in a group of 60 physically healthy mental 
patients who were given succinylcholine before 
electroshock therapy. They carefully controlled 
their conditions to ensure reproducibility. A given 
dose consistently resulted in the same length of 
apnea in a particular person. Each patient received a 
different succinylcholine dose at intervals of days 
or weeks. A direct relationship was found between 
dose and duration of apnea and results for four 
patients of various cholinesterase genotypes are 
shown in Fig. 2. 
Examples from Kalow and Gunn (1957) of 
the duration of apnea following a dose of 100 mg 
succinylcholine are 3-6 min apnea in 51 persons with 
usual cholinesterase, 5-12rain apnea in 6 persons 
with usual-atypical cholinesterase, and 50-65min 
apnea in 3 persons homozygous for atypical cholin- 
esterase. While length of apnea was related to activity 
level in persons with usual cholinesterase, it was 
unrelated to cholinesterase activity level in persons 
with atypical cholinesterase, a result which supported 
the conclusion that atypical cholinesterase hydro- 
lyzed none of the succinylcholine. 
Viby-Mogensen (1981a) studied neuromuscular 
blockade in heterozygote patients who had received 
succinylcholine at a dose of 1 mg/kg. The number of 
patients with each genotype and the mean time to 
90% recovery of twitch height was as follows: 28 UA 
(14.6 min), 8 US (12.4 min), 3 UF (12.0 min), 3 AF 
(30 min), and 1 FS (30 min). Recovery in all hetero- 
zygotes was prolonged compared to patients with the 
normal cholinesterase genotype (9.3 min). 
Duration of apnea in 70 patients with usual 
cholinesterase who received 1 mg succinylcholine per 
kg body weight (Viby-Mogensen, 1980) was found 
to increase with decreasing plasma cholinesterase 
activity (Fig. 3). Persons with high activity had 4 min 
apnea, persons with normal activity had 6 min apnea, 
and persons with low activity had 8 min apnea. Even 
the lowest cholinesterase activity (200 #mol benzoyl- 
choline per min per liter of plasma) had only 22 min 
apnea. 
Succinylcholine can be given to people with 
atypical cholinesterase but the dose must be lowered 
to 1% of the normal dose to achieve 5 min of apnea. 
Cohen et  al. (1970) found that 1 mg succinylcholine 
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FIG. 2. Relation between dose of succinylcholine chloride and duration of apuea. Various doses were 
administered at intervals of days or weeks for electroshock treatment. The 4 representative patients have 
atypical (AA), atypical fluoride (AF), a low level of usual (UU), and a high level of usual cholinesterase 
(UU) (Kalow, 1962a, b). Reprinted with the permission of the author and the copyright holders, W. B. 
Saunders, Philadelphia and the Macmillan Publishing Company, New York. 
resulted in 5 min apnea. Lee-Son et  al. (1975) and 
Azar and Betcher (1981) administered a cumulative 
dose of 6-8 mg to atypical cholinesterase patients 
who resumed spontaneous respiration 1-10 min after 
the last dose. 
Under normal conditions, clinical doses of 
succinylcholine do not cross the placenta. However, 
in atypical homozygotic mothers, a clinical dose 
becomes a relative overdose which crosses the placen- 
tal barrier and results in prolonged apnea of the 
newborn. In two case reports infants suffered 
transient respiratory depression when the mother's 
cholinesterase genotype was homozygous atypical 
and the infant's genotype was either homozygous 
atypical or atypical-usual (Baraka et  al., 1975; 
Hoefnagel e t  al., 1979). 
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FIG. 3. Correlation between cholinesterase activity and time 
to recovery of 100% twitch height. 70 patients of the usual 
cholinesterase genotype received a dose of 1 mg/kg succinyl- 
choline intravenously. Recovery of twitch was monitored by 
train-of-four nerve stimulation. The fitted regression line 
and 95% prediction region are shown. Arrows indicate the 
normal range of cholinesterase activity in genotypically 
normal patients (Viby-Mogensen, 1983). Reprinted with the 
permission of the author and the copyright holder, the 
Danish Medical Association, Copenhagen. 
2.5. NOT ALL CASES OF PROLONGED APNEA FOLLOWING 
THE USE OF SUCCINYLCHOLINE CAN BE EXPLAINED BY 
GENETIC VARIANTS OF SERUM CHOLINESTERASE 
The Danish Cholinesterase Research Unit tests 
sera of all persons in Denmark who respond abnor- 
mally to succinylcholine. A 4 year summary report 
of 225 cases (Viby-Mogensen and Hanel, 1978) 
showed that 64% of these cases had at least one 
abnormal cholinesterase gene, 6% had low cholin- 
esterase activity due to an acquired deficiency (for 
example liver disease) while the remaining 28% had 
normal activity and normal genotype. Similarly, the 
Cholinesterase Research Unit in England directed 
by Mary Whittaker found that 65% of succinyl- 
choline apneas were associated with genetic variants 
of cholinesterase (Whittaker, 1980). A summary 
of eight surveys reviewed by Whittaker (1980, 
1986) shows that 65% of 1121 succinylcholine- 
sensitive individuals carried at least one abnormal 
cholinesterase gene. 
What explanations are available for the 35% who 
had the usual cholinesterase genotype, but neverthe- 
less displayed unusually long periods of apnea after 
the administration of succinylcholine? In 77 succinyl- 
choline-sensitive patients of genotype UU, prolonged 
apnea in 34 patients was due to factors other than 
standard use of succinylcholine (Viby-Mogensen and 
Hanel, 1978). These factors were hyperventilation or 
respiratory depression caused by overdose with an 
inhalation anesthetic or a nondepolarizing neuro- 
muscular blocking agent, or succinylcholine over- 
dose. In 14 cases prolonged apnea was explained 
by low cholinesterase activity; low activity was 
caused by liver diseases, chronic debilitating diseases, 
carcinoma, or by anticholinesterase drugs such as 
echothiopate eye drops. In 29 patients the reason for 
the prolonged apnea could not be established and 
the possibility existed that these cases represented 
unknown genotypes. 
Reviews by Whittaker (1980, 1986) and Viby- 
Mogensen (1985) list causes of decreased plasma 
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cholinesterase activity. Having a rare cholinesterase 
genotype is just one possible cause of low activity. 
During pregnancy activity can fall 20--30% partly due 
to hemodilution and partly to reduced synthesis by 
liver, with activity being lowest on the 3rd day after 
delivery. The newborn has about 50% of normal 
activity and reaches normal levels at 3-4 years of age. 
Diseases which affect synthesis of cholinesterase by 
liver, for example, acute hepatitis, liver metastasis, 
and liver cirrhosis, often reduce activity to 50%. 
Activity can be low in cholecystitis, renal disease, 
myocardial infarction, muscular dystrophy, con- 
genital myotonia, dermatomyositis, hyperpyrexia, 
rheumatic fever, typhus, tetanus, tuberculosis, acute 
infections, carcinomas, chronic debilitating diseases, 
chronic anemias, epilepsy, myxodema and uremia. 
Malignant tumors of the gastrointestinal tract and 
lung appear to depress cholinesterase more than 
tumors located elsewhere, and activity can fall 
below 25% of normal. In burn patients activity 
can fall to 20% of normal. Surgical shock, X-ray 
therapy, and kidney dialysis can reduce activity. 
Organophosphates, such as in pesticides (paraoxon) 
and certain anticancer drugs (cyclophosphamide, 
Endoxan, Thio-tepa) irreversibly inhibit cholin- 
esterase. Patients treated with Endoxan or Thio-tepa 
have 35-70% of normal activity. Echothiopate eye 
drops used one drop in each eye twice a day can 
reduce activity to nearly zero. After discontinuation 
of treatment with organophosphate drugs it can 
take two weeks to regain 70% of normal activity 
and 6-8 weeks to regain full activity, because 
the cholinesterase must be newly synthesized by 
the liver. Reversible cholinesterase inhibitors that 
depress activity transiently are bambuterol (Fisher 
et al., 1988), edrophonium, neostigmine, and pyrido- 
stigmine. Other drugs that depress activity are 
monoamine oxidase inhibitors, contraceptive pills, 
propanidid, chlorpromazine, pancuronium, and local 
anesthetics. Activity can be severely depressed in 
kwashiorkor and malnutrition. 
What level of usual cholinesterase activity is con- 
sidered low for purposes of predicting succinylcholine 
apnea? Activities of 154--543#mol benzoylcholine 
per min per liter of plasma were found in 14 succinyl- 
choline-sensitive patients of the usual genotype. The 
normal activity range is 690-1560 U/L. In this group 
of patients the dose of succinylcholine ranged from 
50--250 mg and the duration of apnea was 15-240 rain 
(Viby-Mogensen and Hanel, 1978). 
2.6. PHENOTYPING PROCEDURES 
2.6.1. Phenotyping by Dibucaine Number 
Problems with succinylcholine are rare, occurring 
in 1 patient per 100 Europeans and Americans. 
Therefore patients are not routinely screened for 
cholinesterase activity and genotype. Testing is 
confined to patients who have a history of succinyl- 
choline apnea and to relatives of such patients. 
It is not possible to discriminate between the 
various cholinesterase genotypes by activity tests 
alone, as shown by Fig. 4. Kalow developed a 
simple method for determining who was a carrier of 
atypical cholinesterase. He introduced the 'Dibucaine 
Number' (DN), which is the percent inhibition of 
hydrolysis of substrate in the presence of 10/~M 
dibucaine (Kalow and Genest, 1957). Figure 5 
illustrates the differential inhibition achieved by 
dibucaine. Usual cholinesterase is very sensitive to 
dibucaine which inhibits 80% of its activity; UU has 
a dibucaine number of 80 (range 77-83). Atypical 
cholinesterase is resistant to dibucaine being inhibited 
only 20% (DN 20; range 8-28), and the heterozygote 
has intermediate sensitivity so that 60% of its activity 
is inhibited (DN 60; range 48--69) (Whittaker, 1986). 
Though other inhibitors also discriminate between 
usual and atypical genotypes, dibucaine was chosen 
because it is readily available, is stable in solution, 
and inhibits immediately. Determination of dibucaine 
number is still the best, most accurate, simplest, and 
most widely used method for cholinesterase pheno- 
typing. The idea of discriminating by means of 
differential sensitivity to an inhibitor has been used 
to identify new genetic variants. Inhibitors includ- 
ing sodium fluoride, RO 2-0683 from Hoffmann- 
La Roche = the dimethylcarbamate of (2-hydroxy-5- 
phenylbenzyl)-trimethylammonium, sodium chloride, 
succinylcholine, butanol, and urea are used to iden- 
tify fluoride, H, J, and K variants. The substrate 
preferred by many laboratories is benzoylcholine 
because benzoylcholine is specifically hydrolyzed by 
serum cholinesterase and not by red cell acetyl- 
cholinesterase, is stable in solution, and has simple 
kinetics. Hospital laboratories often prefer butyryl- 
thiocholine or propionylthiocholine because these 
substrates are suitable for single time point assays on 
an automated analyzer. Dibucaine numbers can be 
measured with any of these substrates, though the 
reference values for interpreting the meaning of a 
measured dibucaine number will differ depending on 
the substrate, temperature and buffer. 
2.6.2. Importance of Nerve Stimulator 
The anesthesiologist can exclude cases of respira- 
tory insufficiency that have no connection with 
cholinesterase levels and genotypes by using a nerve 
stimulator. If no neuromuscular block is observed 
with the nerve stimulator then succinylcholine is not 
involved. However, the presence of a phase II neuro- 
muscular block following a single normal dose of 
succinylcholine indicates an abnormal cholinesterase 
genotype (Viby-Mogensen, 1983). This simple test in 
the operating room eliminates 15-20% of cases from 
further consideration. The nerve stimulator can give 
a preliminary idea of the cholinesterase phenotype. 
By using the nerve stimulator and observing time 
to spontaneous recovery, Viby-Mogensen can dis- 
criminate between patients with genotype AF or FS, 
and patients with AA, AS or SS genotypes. 
2.6.3. Polymerase Chain Reaction Jbllowed by DNA 
sequencing 
This procedure was first used for cholinesterase by 
McGuire et al. (1989). It is based on knowledge of the 
nucleotide sequence of human serum cholinesterase 
including the complete coding sequence as well as 
intron sequences near exon/intron boundaries. The 
DNA sequence is required to design oligonucleotide 
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FIG. 4. Dibucaine number separates AA, UA, and UU genotypes into three groups, in contrast to activity 
measurement which gives only one group. The frequency distribution of dibucaine numbers among 135 
members of seven unrelated families is shown in the top graph. The same sera were tested for activity 
and results are shown in the bottom graph• The black columns show esterase activity of sera with dibucaine 
number below 70 (Kalow and Staron, 1957). Reprinted with the permission of the authors and the 
copyright holder, The National Research Council of Canada, Ottawa. 
primers that match the cholinesterase gene at the 
beginning and end of the region to be examined. The 
oligonucleotides are used to prime amplification of 
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FIG. 5. Percentage inhibition of activity of usual and atypical 
cholinesterases by different concentrations of dibucaine. 
Optimal discrimination between usual and atypical 
cholinesterases was obtained with 10-sM dibucaine. Activ- 
ity was measured spectrophotometrically with benzoyl- 
choline as substrate (Kalow and Genest, 1957). Reprinted 
with the permission of the authors and the copyright holder, 
the National Research Council of Canada, Ottawa• 
We usually obtain 20 ml of whole blood in citrate 
anticoagulant from each donor. DNA is prepared 
from the white cells in the buffy coat. A small aliquot 
of this genomic DNA is amplified by means of 
the polymerase chain reaction, yielding millions of 
copies of a segment of the cholinesterase DNA. The 
amplified, double-stranded cholinesterase DNA is 
sequenced by a modification of the Sanger dideoxy 
sequencing procedure. An example of sequencing 
results is in Fig. 6. Best results are obtained when 
the amplified fragment is short, 200--400 base pairs. 
Since the cholinesterase mRNA is 2.4 kilobase pairs 
in length, the procedure has to be repeated about 10 
times to obtain the complete sequence of a new 
variant. However, genotyping is much simpler once 
the nucleotide alterations are known, because ampli- 
fication and sequencing can focus on just one region. 
Kalow's phenotyping method remains an essential 
prerequisite before launching into a week-long pro- 
ject for determination of DNA sequence. To date 
the correlation between dibucaine number and DNA 
sequencing results has been perfect for the atypical 
locus. 
2.7. DRUGS HYDROLYZED BY CHOLINESTERASE 
A list of ester drugs hydrolyzed by cholinesterase 
is in Table 2. K m values for hydrolysis by both usual 
and atypical cholinesterases are in Table 3. The K~ 
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FIG. 6. DNA sequences of usual (UU), heterozygous (UA), and atypical (AA) cholinesterases showing the 
nucleotide substitution in atypical cholinesterase. Total genomic DNA from three individuals was 
amplified by the polymerase chain reaction with oligonucleotides corresponding to the coding region of 
the cholinesterase gene. Both strands of the double-stranded, amplified DNA were sequenced simulta- 
neously. The sequences are identical except for the nucleotide marked with a star. Codon 70 is GAT in 
UU, GAT and GGT in UA, and GGT in AA (McGuire et al., 1989). 
values show that atypical has a lower affinity for these 
compounds and therefore slower hydrolysis at clini- 
cal doses. Succinylcholine and cocaine are not hy- 
drolyzed by atypical cholinesterase at doses found in 
circulating blood (Goedde et al., 1968; Stewart et al., 
1977), though they are hydrolyzed by usual cholin- 
esterase. It is likely that most of the drug esters in 
Table 2 are poorer substrates for atypical cholin- 
esterase than for usual cholinesterase when measure- 
ments are made with low drug concentrations. 
However, the extrapolated rate obtained from a 
Lineweaver-Burk plot, that is, the maximum rate of 
hydrolysis at saturating substrate concentration, has 
the same value for both atypical and usual cholin- 
esterases. This extrapolated maximum hydrolysis 
rate is shown in Table 2 as turnover number. These 
values indicate that the best substrates are aspirin, 
meprylcaine, isobucaine and chloroprocaine and 
the poorest are cocaine and aprophen. All drugs in 
Table 2 are hydrolyzed slowly compared to esters 
commonly used as substrates, namely benzoylcholine 
and butyrylthiocholine. 
Four case reports suggest that procaine and chloro- 
procaine may have prolonged or toxic effects in 
people with atypical or silent cholinesterase (Downs, 
1966; Zsigrnond and Eilderton, 1968; Doenicke et al., 
1963; Kuhnert et al., 1982). Procaine applied to the 
skin of a person with silent cholinesterase had a 
prolonged effect lasting more than 160min, com- 
pared to the normal 25 min (Doenicke et  al., 1963). 
Chloroprocaine injected for epidural anesthesia had 
an abnormally long duration of approximately 3 hr in 
a patient with atypical cholinesterase; normally the 
block lasts 45~0  min (Kuhnert et  al., 1982). How- 
ever, Raj et al. (1977) saw no increase in the duration 
of block in an atypical cholinesterase patient who 
received chloroprocaine. In clinical practice today 
procaine is rarely used and therefore problems are 
TABLE 2. Drugs Hydrolyzed by Human Serum Cholinesterase 
Turnover 
Drug ester Use Effect of ChE number Reference 
Succinylcholine Depolarizing muscle Inactivate 300 Goedde et al., 1968 
relaxant 
Procaine Local anesthetic Inactivate 255 Valentino et al., 1981 
2-Chloroprocaine Local anesthetic Inactivate 1,200 Foldes et al., 1965 
Meprylcaine Local anesthetic Inactivate 2,750 Foldes et al., 1965 
Isobucaine Local anesthetic Inactivate 2,250 Foldes et al., 1965 
Tetracaine Local anesthetic Inactivate 74 Valentino et al., 1981 
Aspirin Analgesic Inactivate 7,200 Valentino et al., 1981 
Heroin Narcotic Convert to 500 Lockridge et al., 1980 
6-acetyl morphine 
Cocaine CNS stimulant and 
Local anesthetic 
Methylprednisolone acetate Anti-inflammatory agent Activate 
Aprophen Antispasmodic and Inactivate 
anticonvulsant 
Mivacurium Nondepolarizing Inactivate 
muscle relaxant 
Bambuterol Bronchodilator Activate 
0.4 Stewart et al., 1977 
25 Myers et al., 1982 
0.12 Rush et al., 1985 
Savarese et al., 1988 
Tunek and Svensson, 1988 
Turnover is the maximal velocity at saturating substrate concentration expressed as mol hydrolyzed per min per mol active 
site. Turnover numbers for succinylcholine, chloroprocaine, meprylcaine, isobucaine, and cocaine are based on data in the 
references and do not appear as such in the references. 
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TABLE 3. K m Values and Turnover Numbers for  Substrates o f  Usual and Atypical Cholinesterase 
K m (mM) Turnover 
Usual Atypical number Reference 
Positively charged 
Acetylcholine C1 1.4 9.0 33,200 Davies et al., 1960 
Propionylcholine I 0.97 3. I 55,000 Davies et al., 1960 
Butyrylcholine I 0.91 1.7 80,000 Davies et al., 1960 
Pentanoylcholine I 0.72 1.5 63,000 Davies et al., 1960 
Hexanoylcholine I 0.57 0.82 36,000 Davies et al., 1960 
Heptanoylcholine I 0.38 1.11 35,000 Davies et al., 1960 
Benzoylcholine CI 0.004 0.022 15,000 Davies et al., 1960; 
Lockridge and La Du, 1978 
Succinyldithiocholine 0.035 1.08 600 Hersh et al., 1974 
Heroin 0.11 0.45 500 Lockridge et al., 1980 
Procaine 0.0066 0.10 255 Valentino et aL, 1981 
Tetracaine 0.00014 0.008 74 Valentino et al., 1981 
N-methyl-(7-dimethyl 0.00008 0.002 0.0025 Lockridge and La Du, 1978 
carbamoxy)quinolinium I 
Neutral 
o-Nitrophenylbutyrate 0.33 0.4 48,000 Valentino et al., 1981 
~-Naphthylacetate 1.0 0.37 36,000 Valentino et al., 1981 
ct-Naphthylacetate 4- 
20 mM CaC1 0.4 0.37 36,000 Valentino et al., 1981 
Methylprednisolone 
acetate 1.0 - -  25 Myers et al., 1982 
Negatively charged 
aspirin + 50 mM CaCI 4.2 16 7,200 Valentino et al., 1981 
Turnover number is defined as the maximal velocity at saturating substrate concentration expressed as mol 
substrate hydrolyzed per min per mol active site. Turnover number is the same for usual and atypical 
cholinesterases. Km and Vm~x were determined at 25°C in pH 7.4 buffer, except for succinylcholine which was at 
30°C. Values in Davies et al. (1960) and Hersh et al. (1974) were converted to turnover numbers (TN) using the 
relationship Vma x ester/Vma x benzoylcholine = TN ester/TN benzoylcholine. 
infrequent. In the rare instances when dentists still use 
procaine (novocaine) as a local anesthetic they inject 
procaine intramuscularly along with a vasoconstric- 
tor. This mode of application makes hydrolysis unim- 
portant and therefore problems are not expected with 
rare cholinesterase variants. 
It is possible but as yet undocumented that people 
with atypical cholinesterase might be unusually sensi- 
tive to heroin. This possibility arose when it was 
found that heroin was hydrolyzed more slowly by 
atypical cholinesterase due to a decreased affinity. 
Serum from a person identified as having silent cholin- 
esterase did not hydrolyze heroin at all (Lockridge 
et  al., 1980). The product of heroin hydrolysis 
by cholinesterase is 6-acetylmorphine. Heroin and 
6-acetylmorphine penetrate the blood- brain barrier 
and are slowly hydrolyzed to the pharmacologically 
active agent, morphine, by enzymes in the brain. 
Cholinesterase does not produce morphine. Cholin- 
esterase is the only enzyme in human serum that 
hydrolyzes heroin, though enzymes in red blood 
cells account for 50-70% of the heroin hydrolysis 
observed in whole blood. 
No association has been made between atypical 
cholinesterase and problems with aspirin or tetra- 
caine even though these compounds are hydrolyzed 
more slowly by atypical cholinesterase (Valentino 
et  al. ,  1981). Methylprednisolone acetate is converted 
to its active form by hydrolysis of the ester bond. 
Cholinesterase in serum accounts for 25% of the 
hydrolysis observed in vivo. This makes it unlikely 
that a person with atypical cholinesterase would have 
an abnormal response to methylprednisolone acetate 
(Myers et  al., 1982). 
Mivacurium chloride is a new short-acting non- 
depolarizing, neuromuscular blocking drug under- 
going clinical trials (Savarese et al., 1988). The diester 
is hydrolyzed by cholinesterase at about the same rate 
as succinylcholine. In individuals who have atypical 
cholinesterase its duration of action may be pro- 
longed though this has not yet been tested. 
Bambuterol is a new dicarbamate prodrug 
especially designed to inhibit cholinesterase, thus 
allowing slow release of the active compound, 
terbutaline. The slow release may allow a person 
to take this antiasthma drug just once a day. 
The potency of bambuterol is similar to that of 
the dimethyicarbamate R02-0683 and of organo- 
phosphate esters, all having 150 of 10-8 to 
10 _9 M, with the difference that carbamate-inhibited 
cholinesterase regains full activity in 24 hr, 
whereas organophosphate-inhibited cholinesterase 
is irreversibly inhibited. Bambuterol taken orally 
10hr before surgery had the effect of prolong- 
ing succinylchotine-induced paralysis in humans 
(Fisher et  al., 1988). The effect of bambuterol in 
atypical cholinesterase patients has not yet been 
studied, but it is known that atypical plasma hydro- 
lyzes bambuterol at a slower rate (Tunek et al., 
1988). Another special feature of bambuterol is 
that it does not inhibit acetylcholinesterase at thera- 
peutic doses. This selective inhibition of cholin- 
esterase is important to the patient because it 
avoids toxic effects. Another consequence is that 
bambuterol di criminates between cholinesterase and 
acetylcholinesterase more selectively than the classic 
iso-OMPA and BW284C51 (Tunek and Svensson, 
1988). 
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2.8. OTHER ESTERASES INVOLVED IN DRUG 
METABOLISM 
Several human enzymes may be involved in 
the hydrolysis of the drug esters in Table 2. Red 
blood cells contain at least three esterases: acetyl- 
cholinesterase, carbonic anhydrase and esterase D. 
Monocytes and lymphocytes contain acid esterase, 
which is also called alpha-naphthyl acetate esterase. 
Serum and plasma contain cholinesterase and 
arylesterase/paraoxonase. Succinylcholine is known 
to be hydrolyzed exclusively by cholinesterase in 
serum and not by acetylcholinesterase in red blood 
cells. However, heroin is hydrolyzed both by serum 
cholinesterase and by other esterases in whole blood, 
though not by arylesterase/paraoxonase in plasma. 
Aprophen is hydrolyzed by serum cholinesterase 
and by liver carboxylesterases, but not by acetyl- 
cholinesterase. Genetic variants are known not 
only for cholinesterase but also for arylesterase/ 
paraoxonase (Eckerson et  al., 1983b), carbonic anhy- 
drase (Venta et al., 1987), and esterase D (Lee and 
Lee, 1986). No genetic variants are known for human 
acetylcholinesterase. 
3. THE USUAL CHOLINESTERASE 
PROTEIN 
To understand the genetic variants we need to 
establish the properties of the usual cholinesterase 
protein. The following summarizes recent structural 
results for usual cholinesterase. 
3.1. PURIFICATION OF USUAL CHOLINESTERASE 
PROTEIN 
Cholinesterase is routinely purified in our labora- 
tory from 10 L of outdated human plasma by a 
three-step procedure. This scaled-up procedure has 
not been previously published though we gave a brief 
description when we introduced the procainamide 
affinity gel (Lockridge and La Du, 1978; Lockridge et 
al., 1979). Figure 7 is an example of purification of 
usual cholinesterase. Details of the purification are in 
the figure legend. The yield from 10 L is 8-12 mg of 
electrophoretically pure cholinesterase. 
Na/K phosphate buffer pH 7.4, at 25°C (Kalow and 
Lindsay, 1955). The buffer contains 75.84 g of anhy- 
drous Na2HPO4 and 18.156 g of anhydrous KH2PO 4 
per 10 L of water, and is sterilized by either filtra- 
tion or autoclaving. The reason for sterilizing the 
buffer is to avoid degradation of benzoylcholine by 
microbes. Activity is measured at 240 nm using an 
extinction coefficient of 6700 M- ' cm- ~ for the differ- 
ence in absorbance between substrate and product. 
Hydrolysis of butyrylthiocholine is measured using 
the Ellman assay modified for cholinesterase (Ralston 
et al., 1983). The reagent concentrations are 1.0 mM 
butyrylthiocholine in 0.1 M sodium phosphate buffer 
pH 8.0, and 0.3 mM DTNB, at 25°C. The extinction 
coefficient for the yellow product is 13,600 M-lCm -1 
at 412 nm. One unit is defined as the amount of 
enzyme that hydrolyzes 1 ~tmol substrate per min. 
Protein concentration is measured by absorbance at 
280 nm, where an absorbance of 1.8 corresponds to 
a concentration of 1 mg/ml. Preparations having a 
specific activity of 200 units/mg with benzoylcholine, 
and a specific activity of 700 units/mg with butyryl- 
thiocholine appear pure on polyacrylamide gel 
electrophoresis, have an amino acid composition that 
agrees with the composition calculated from the 
amino acid sequence, and have a single N-terminal 
sequence. These highly purified preparations still 
contain trace amounts of peptidase contaminants (see 
below). 
We prefer benzoylcholine over butyrylthiocholine 
for assaying serum samples and for studies in which 
activity is measured at a range of substrate concentra- 
tions (for example, Km and K~ determinations) for 2 
reasons. (1) Benzoylcholine is specifically hydrolyzed 
by cholinesterase and not by acetyicholinesterase; 
butyrylthiocholine on the other hand is hydrolyzed 
by both enzymes and there can be some activity from 
acetylcholinesterase released from red blood cells. 
(2) Benzoylcholine has simple kinetics so that a 
Lineweaver-Burk plot for the range 0.013-0.10 mM 
benzoylcholine gives a straight line; in contrast, 
butyrylthiocholine has complicated kinetics even with 
highly purified cholinesterase. A Lineweaver-Burk 
plot gives a curve for the range 0.6-10 mM butyryl- 
thiocholine. 
3.3. MOLECULAR WEIGHT 
3.2. SPECIFIC ACTIVITY OF ELECTROPHORETICALLY 
PURE CHOLINESTERASE 
There is wide variety in the literature regarding 
the specific activity of human serum cholinesterase 
preparations that are considered pure. The following 
specific activity values are the highest obtained by 
us, and are higher than those reported by other 
laboratories. For the substrate benzoylcholine, the 
specific activity is 200/~mol benzoylcholine hydro- 
lyzed per minute per mg protein; for the substrate 
butyrylthiocholine, the specific activity is 700/~mol 
butyrylthiocholine hydrolyzed per minute per mg 
protein. 
Specific activity is measured using either benzoyl- 
choline or butyrylthiocholine. Benzoylcholine activity 
is measured with 0.05 mM benzoylcholine in 0.067 M 
The 574 amino acids in the subunit have a weight 
of 65,092 (Lockridge et al., 1987b). The nine carbo- 
hydrate chains in each subunit contribute 23.9% of 
the final weight so that the total weight of the sub- 
unit is 85,534. The molecule is a tetramer of 4 
identical subunits and thus the enzyme molecular 
weight is 342,136. This value is approximate because 
the weight of carbohydrate is not exact. Sizes deter- 
mined by other methods are in agreement with the 
size obtained by amino acid sequencing. Molecular 
weights of the monomer and dimer are 90,000 and 
180,000 respectively, on SDS gel electrophoresis. 
The subunit weight is 85,000 on ultracentrifugation, 
81,000 and 86,000 on Sephadex gel filtration, and 
100,000 when titrated with DFP or paraoxon. The 
molecular weight of the tetramer is 348,000 by ultra- 
centrifugation. 
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3.4. PROTEASE CONTAMINATION 
Unidentified blood proteases copurify with serum 
cholinesterase in the early steps of the purification. 
However, protease contaminants are absent in cholin- 
esterase that is electrophoretically homogeneous. We 
observed the effects of these protease contaminants 
during amino acid sequencing. When a 65-75% pure 
preparation (130-150 units/mg) was used for amino 
acid sequencing, peptides with unexpected termini 
were obtained. This problem was absent when more 
highly purified preparations were used. 
There is other evidence of protease contamination 
in partially purified cholinesterase. Such preparations 
are unstable in solution at 4°C. In contrast, our 
purest preparations are stable for years at 4°C in pH 7 
phosphate buffer containing 0.1 mM EDTA. Another 
way of seeing the effects of the protease contaminants 
is by polyacrylamide gel electrophoresis followed by 
staining for cholinesterase activity; over a period of 
months of storage the enzyme, which is normally a 
tetramer, partially degrades to the smaller C1 and C3 
'isozymes'. The same result can be obtained in a few 
hours by adding trypsin (Lockridge and La Du, 
1982). The effects of limited proteolysis may not show 
up in activity assays, because the partially proteo- 
lyzed molecule can be fully active. The proteolysis 
may not be evident on sucrose gradient centrifugation 
since the great majority of the partially proteolyzed 
cholinesterase is still a tetramer. 
The most sensitive way to find out whether a 
purified cholinesterase preparation has undergone 
some proteolysis is to subject the cholinesterase to 
SDS gel electrophoresis in the absence of added 
mercaptoethanol or dithiothreitol. Under these con- 
ditions the native tetramer is dissociated into dimers. 
Any material having a monomer size of 85,000 
daltons is the result of proteolysis. The relative 
amount of monomer to dimer gives an estimate of 
the extent of proteolysis. If a single dimer band of 
170,000 daltons is obtained, then the cholinesterase 
is intact. 
Commercially purified human cholinesterase is 
often only partially pure and is highly likely to 
contain proteolytic nicks. Studies using commercial 
cholinesterase should keep in mind that physical par- 
ameters may be altered and complicated by the pro- 
teolytic nicking. For example, heat stability may be 
reduced to well below the normal half-life of 54 min 
at 55°C. Cholase from Behringwerke AG is 5.5% 
pure. This is the preparation used successfully by 
the Danish Cholinesterase Research Unit to reverse 
succinylcholine apnea (Viby-Mogensen, 1981b). 
3.5. PEPTIDASE CONTAMINATION 
Our most highly purified cholinesterase prepara- 
tion had the ability to hydrolyze the peptide hor- 
mone, Substance P (Lockridge, 1982). The rate 
of hydrolysis was very slow requiring 0.2mg of 
cholinesterase over a period of 48 hr to hydrolyze 
0.2 mg of Substance P. Several laboratories agreed 
that highly purified cholinesterase was capable of 
hydrolyzing Substance P. However, the interpreta- 
tion of  Nausch and Heymann (1985) and Kaemmer 
et  al. (1986) was that the enzyme catalyzing this 
hydrolysis was a contaminant, identified as dipeptidyl 
peptidase IV. The evidence supporting this interpre- 
tation was that the ester hydrolyzing activity of 
cholinesterase was completely inhibited by physostig- 
mine (eserine) without affecting Substance P degrad- 
ing activity. Conversely, an inhibitor of dipeptidyl 
peptidase IV inhibited peptidase activity more than 
esterase activity. In addition, Chatonnet and Masson 
(1985) showed that two different DFP sensitive sites 
were responsible for hydrolysis of the ester and the 
peptide. The peptidase contaminant cannot be seen 
on SDS gels stained for protein or by measuring 
radioactivity from bound DFP in gel slices because 
the contaminant comigrates with cholinesterase 
(Chatonnet and Masson, 1986). In separate studies, 
Boopathy and Balasubramanian (1987) reported a 
peptide cleavage specificity and inhibition sensitivity 
in cholinesterase preparations that was not character- 
istic of dipeptidylamino peptidase IV, but could be 
due to a different peptidase. The amount of peptidase 
contaminant is probably no greater than 1-3% by 
weight. 
Despite the above arguments that peptidase activ- 
ity is from a contaminant, the issue is not yet settled. 
The possibility that cholinesterase has a second activ- 
ity and even a second active site has not been ruled 
out. The idea of a second active site is supported by 
studies with acetylcholinesterase where numerous 
reports suggest that acetylcholinesterase from various 
sources including electric eel (Small et al., 1987), 
sheep basal ganglia (Majumdar et  al., 1988), and fetal 
calf serum (Small, 1988) has peptidase activity and 
that its function in noncholinergic tissues is to process 
neuropeptides. Fasciculin is a 61 amino acid peptide 
from the venom of green mamba snake. It is a 
powerful inhibitor of both acetylcholinesterase and 
cholinesterase, leaving no doubt that these enzymes 
have the ability to bind a peptide (Mbugua and 
Karlsson, 1985). 
3,6. SDS GEL ELECTOPHORESIS 
On SDS gel electrophoresis cholinesterase has a 
single dimeric band of 170,000-180,000 daltons in the 
absence of mercaptoethanol and dithiothreitol. In 
the presence of reducing agent, there are two bands: 
a major band at 85,000-90,000 daltons and a minor 
band at 170,000-180,000daltons (Lockridge et al., 
1979). The 85,000 band is the monomeric subunit, 
while the 170,000 band is residual unreduced dimer. 
If a preparation shows both bands in the absence of 
reducing agent, then the cholinesterase has under- 
gone partial proteolysis resulting in removal of a 
small peptide from the C-terminal containing the 
interchain disulfide bond (Lockridge and La Du, 
1982). The partially proteolysed monomer has the 
same apparent molecular weight as intact monomer. 
The interchain disulfide bond is located 4 amino 
acids from the end of the subunit (Lockridge et al., 
1987a). Therefore proteolytic removal of these 4 
amino acids does not significantly alter the subunit 
weight. Boiling the enzyme for l0 rain or longer in 
the loading buffer for SDS gels (5% glycerol, 1% 
SDS) creates artifacts by degrading the dimer into 
several small bands including a heavy monomer sized 
band. 
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Cholinesterase bands  are b road  on SDS gels 
because of  the high ca rbohydra t e  content  of  23.9% 
by weight. This prevents  detect ion of  small  changes  
in size, and  prevents  accurate  ass ignment  of  size on 
SDS gels. 
3.7. AMINO ACID SEQUENCE 
The complete  amino acid sequence of h u m a n  
serum cholinesterase was determined by E d m a n  
degradat ion of  overlapping peptides (Lockridge e t  al. ,  
-212 AC TGA ATG TCA GTG CAG TCC AAT TrA CA(; GCT 
Pvu II 
GG~ GCA GCA GCT GCA TCC TGC ATT TCC CCG AAG TAT TAC ATG A~T ~ ACT CCT TGC AAA CTT TAC CAT CTT TGT TGC AC~ GAA TCG C~A 
-28 -1 
Met His Sat Lys val ~nr Ile Ile Cys Ile Arg Phe Leu Phe Trp Phe Leu Leu Leu Cys Met Leu Ile Gly Lys Set His Thr 
ATC AAT ATG (~%T AGC AAA GTC ACA ATC ATA TGC ATC AC~% TTT CTC TIT TGG TTT CTT TTG CTC TC~ ATG CIT ATT GGG AAG TCA CAT ACT 
+1 i~?--- ClIO 20 30 
G1 u-Asp-ASp- I i e- I I e- I i e-Al a- Thr-Lys-Asn-GI y-Lys-val-Arg-Gl y-Me t-Asn-Leu-Tn r -val-Phe-Gl y-Gl y-Thr-Val-Thr-Al a-Phe-Leu-Gl y- 
GAA C~%T C~tC ATC ATA ATr GCA ACA AAG AAT GGA AAA GTC AGA GGG A~ AAC TTG ACA GTT TI~ GGT GGC ACG G~ ACA GCC TTT CT~ GC~% 90 
40 50 CHO ~q~ 
1 le-Pro-Ty~-Ala-Gln-Pro-P co-Leu-Gly-Arg-Leu-A~g-phe-Lys-Lys- p ~o-Gln-Se r-Leu-Thr-Lys-Trp-Se r-Asp-I le-Trp-Asn-Ala-Thr-Lys- 
A~T CCC ~%T GCA CAG CCA CCT CIT GGT AGA CIT CGA TTC AAA AR~ CCA CAG TCT CTG ACC AAG TGG TCT C~%T ATT TGG AAT ~ ~ ~ 180 
Sco ~ i - '~1 80 90 
Tyr-Ala-Asn-Se r-Cys-Cys-Gln-Asn-I le I AsP I Gln-Se r-phe-Pro-Gly- phe-Hi s-Gly-Se r-Glu-Net-Trp-Asn-P co-Asn-Th r-Asp-Leu-Se r-GIu- 
TAT GCA AAT ~ 'IV.,C ~ CAG AAC ATAIr_.-aTICAA AGT TIT CCA C_,GC TIC CAT GGA TCA GAG A'£G ~ AAC CCA ~ ACT ~ ~ ~ ~ 270 
ClIO 110 11171 120 
A s p - C ~ - L e u - - T y r - l . , e u - A s n - V a l - T r p -  1 l e - P  ro--Ala-P r o - r . y s - P r O - L y s - A m a - A l a - T h r - V a l - L e u - I  1 P T r p - I  le--T, / r-Gly--Gly I G l y  I Phe - -~ ln -Thr -  
C~E 'IL,-'T T I~  TAT C'I~. AAT G'I~ TGG ATr CCA GCA C'CT AAA CCA AAA AAT C42C ACT G ~  T ~  ATA TGG ATT TAT GGT GGTIGGTITTT C.AA ACT 360 
130 140 150 
G1 y- ~ r-Se ~-Se r-LeU-Hi s-Val-Tyr -ASp-G1 y-Lys-Phe-beu-Al a-A/g- val -G1 u-At 9-Va I- I le-va l-Val-Se r-Met-ASh- Tyr -A/g-Val -G1 y-Al a- 
GC~% ACA TCA TCT T~% CAT GTT TAT C~%T GGC AAG ~IT CIG GCT CGG GTT G~A AC~% GZT A~T GTA GTG TCA ATG ~ TAT ~ ~ ~ ~ 450 
160 170 180 
Leu-Gly-Phe-Leu-Al a-Leu-P r o-GIy-Asn-P r o-Glu-AIa-P r o-G1 y-ASh- Me t -Gly-Leu-Phe-Asp-Gln-Gln-Leu-Ala-Leu-Gln-T rp-Va 1-Gln-bys - 
C/~ GGA TTC ~-A GCT TTG CCA GGA AAT CCT C~%G GCT CCA GGG A~J: ATG GGT TTA TTT G~T ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 540 
190 * 200 210 
ASh- I le-Al a-Al a-Phe-Gly-Giy-Asn-P r o-Lys-Se ~ -Va 1 -Th r -Leu-Phe- GIy-GIu-SER-AI a-Gly-Al a-Ala-Se r -Va l-Se r-Leu-Hi s-~-~u-~ ~- 
AAT ATA GCA GCC ~IT GGT G~% AAT CCT AAA AGT GTA ACT CTC ~'F~ GGA C~%A AGT GCA GC~% GCA GCT TCA GTT AGC CIG CAT ~=I~3 CTT TCT 630 
220 230 240 
Pr o-Gly-Se r - H i s - S e t  -Leu-Phe-~nr-Ar  g - A l a - I  le-Leu-Gln-Se r -G ly -  Ser.Phe-A~n-Ala-P r ~ T ~ a - V a l - ~  r - ~  r - ~ - ~ r ~ u - ~ a ~  
CCT GC~, AGC CAT TCA TI~G T~C ACC AC.~ GCC A ~  CTG CAA AGT GGA TCC T IT  AAT GCT CCT TGG GCG GTA ACA TCT C'IT TAT GAA GCT AGG 720 
(~10 250 ~ ~ 260 270 
ASh-At g-Th ~-Leu-Asn-Leu-AIa-LyS-Leu-Th r -G1y-Cys-Se r -At g-Glu- Am1-Glu-Th r-Gl u- I i e- I I e-Lys-Cys-Leu-Ar g-Asn-Lys-Asp-P ~o-GI n- 
A~: AG~ ACG TTG AAC T~A GCT AAA TTG ACT GGT TGC TCT AGA G~G AAT G~G ACT GAA ~ A~ ~ ~ ~ ~ ~T ~ ~T ~ ~ 810 
280 Xba I 290 300 
Glu- 11 e-Leu-Leu-Asn-Gl u-Al a-Phe-Val -Val-P ro-Tyr -Gly-Th r-P r o- Xau-Se r -val-Asn-Phe-Gly-Pr o-~n r -Val -Asp-Gly-Asp-Phe-~ r - 
C~A AT~ CTT CTG AAT GRA GCA TTT GTT GTC CCC TAT GGG ACT CCT TTG TCA G~% AAC ~T GGT CCG ACC GTG GAT GGT GAT TTT CTC ACT 900 
310 320 330 
Asp-Me t-Pr O-ASp- I le-Llna-Leu-Glu-Leu-Gly-Gl n-Phe-Ly~-Lys-Th r - Gln-I i e-Leu-Val-Gly-Val -Asn-Lys-Asp-Glu-Gly-Th r-Al a-phe- Leu- 
G%C ATG CCA G~C ATR TTA C~T GAA CTT GGA CAA TTT AAA AAA AEC CAG ATT TIG GTG GGT GTT AAT ~ ~T ~ ~ ~ ~ ~ ~ 990 
340 ~ 350 360 
Val-Tyr-Gly-Ala-Prc-Giy-Phe-Se ~-LyS-ASp-ASn-ASn-Se r -I le- I le- Thr-Ar g-Lys-Glu-Phe-Gln-Glu-Gly-Leu-Lys- I le-Phe-Phe-P r~Iy- 
GTC ~%T GGT GCT CCT GGC TTC AGC AAA G~T AAC AAT AGT ATC ATA ACT AGA AAA C~A T~T CAG C~A GGT T~A AAA ATA TI~ TTT CCA GC~% 1080 
370 380 390 
Val-Ser-Glu-Phe-Gly-Lys-Glu-Se r-I le-Leu-Phe-His-T~r -Thr-Asp- T rp-Va 1 -Asp-Asp-GIn-At g-P r o-Glu-Asn-Tyr -At g-Glu-Al a-Leu-Gl y- 
GT~ AGT C~%G TTT GC~% AAG C~A TCC ATC CTT TTT CAT T~C ACA C~%C T~G GT~ G~T C~%T CA~ AC~% CCT C~A AAC ~ ~ ~ ~ ~ ~ 1170 
400 410 420 
AsD-VaI-Val -Gl]{-Asp- Ty~-Asn-Phe- I I e-Cys-Pr o-Al a-Leu-Gl u-Phe- Thr-Lys-Lys-Phe-Se r -431 u- Trp-Gl y-Asn-Asn-AI a-Phe-Phe-T~r - Tyr- 
C~%T GTT GTT GGG Ca%T TAT AAT ~TC A~A TGC CCT GCC TTG GAG T~C ACC AAG ARG ~ T(~% C~A TGG GG~ AAT AAT GCC TTT ~C TAC TAT 1260 
430 440 450 
Phe-Glu-His-Arg-Ser-Se r -Lys-Leu-Pro-Trp-Pro-Glu-Trp-Met-Gly- val-Met-Hl s-Gly-T~r-Glu- 1 le~Glu-Phe-Val-Phe-Gly-Leu-Prc-Leu- 
TI~ C~%A CAC CCa% TCC TCC AAA CTT CCG TGG CCA GAA TGG ATG GC~% GTG ATG CAT GGC TAT C~%A AT~ GAA T~T GTC TIT GGT TTA CCT CTG 1350 
(~qO 460 470 480 
Glu-Ar g-A~9-ASp-Asn-T]{ r -Th r -Lys-Ala-Glu-Glu- I i e-Leu-Se r -At g- Se E-- I le-Val-Lys-Ar g-T r p-Ala-~,~n-Phe-Al a- Lys-Tyr-Gly-Asn-p r O- 
GAA AC~% AC~% C~%T AAT T~%C ACA AAA GCC &%G GAA ATT TTG AGT AGA TCC ATA GT~ AAA CGT TGG GCA AAT TIT GCA AAA TAT GGG AAT CCA 1440 
CH0 C~0 490 500 510 
Asn-Glu-Thr-Gl n-Asn-Asn--Se r-Thr-Se r -Trp-Pro-Val-Phe-Lys-Se r -~hr-Glu-Gln-Lys-Tyr-Leu-Thr-Leu-Asn-Thr-Glu-Se r-Thr-Arg- i Ie- 
AAT GAG ACT CAG AAC AAT AGC ACA AGC TGG CCT GTC TTC AAA AGC ACT GAA CAA AAA TAT CTA ACC TTG AAT ACA GAG TCA ~F.A AC~% ATA 1530 
520 530 Hinc II I~Jl 
Me t-Th r-Lys-Leu-Ar g-Al a-G1 n-Gln-Cys-Arg-Phe-T r p-Th ~-Se r-Phe-Phe-P r o-Ly$-Va 1 -Leu-G1 u-Me t-Th r -Gly-Asn- 1 le-Asp-Glu I Ala I Glu- 
ATG AEG AAA CTA CGT GCT CAA CAA TGT CC~% TI~ TGG ACA TCA TIT TIT CCA AAA GTC TTG C~A ATG ACA GGA AAT AT~ CAT ~ I ~ I ~  1620 
550 560 - -  570 
Trp-GIu-Tr p-Ly~-Ala-Gly-Phe-Hl s-Ar g-Trp-Asn-Asn-Ty r -Met -Me t- ASp-Trp-Lys-Asn-GI ~-phe-Asn-Asp-Tyr -Th r -Se r - Lys-Ly$-Gl u-Se r - 
TGG C~ TGG AAA GCA (~ TTC CAT CGC TGG A~ AAT TAC ATG ATG C~.C TGG AAA ~T ~ ~ ~ ~T ~ ~ ~ ~ ~ ~ ~ 1710 
574 
Cys-Val-Gly-Leu *** 
• GT GTG GGT CTC TAA ~ ATA GAT ~ CCC T~ ATA GAA CAT ATT TTC CTT TAG ATC AAG GCA RAA ATA TCA GGA C~ ~ ~ CAC ~C 1800 
TAC TAA AAA AGT TAT TAT GTA GCT GAA ACA AAA ATG CCA GAA GGA TAA TAT TGA T~C CTC ACA TCT T~A ACT TAG TAT TTT ACC TAG CAT 1890 
T~C RAA ACC CAA AT~ GCT AGA ACA TGT TTA AT~ AAA TIT CAC AAT ATA AAG T~C T~C AGT ~A T/~ TGT GCA TAT TAA AAC AAT GGC CTG 1980 
CAA ~T C~T TCT TTC CTT aat aaa TI~ AAG ~I~ TT~ CCC CCC AAA ATT ATC AGT GCT CTG CTT TTA GTC ACG ~ ATT TTC ATT ACC 2070 
ACT CGT AAA AAG G~A TCT TI~ T~A AAT C~A TTA AAT ATT C~A ACA CTG T~C ~/~C ATA GTT TAC AAT ATT ATG TIT CCT AAT TAA AAT AAG 2160 
AAT TGA ATG TCA ATA T~% GAT ATT AAA ATA AGC ACA C~A AAT CAA AAA AAA AAA 2214 
FIG. 8. Amino acid and nucleotide sequence of human cholinesterase of the usual genotype. The amino 
acid sequence was determined by Edman degradation of overlapping peptides (Lockridge et al., 1987b). 
The N-terminal amino acid of the protein circulating in human serum is glutamic acid (Glu + 1). 
Carbohydrate chains (CHO) are attached to the nine indicated asparagines. The active site serine is Ser 
198. The cDNA contains a total of 2426 nucleotides (McTiernan et al., 1987). Five ATG codons in the 
5' region are underlined because they are potential translation initiation sites. The most likely start site 
is at Met-28, yielding a signal peptide of 28 amino acids. The polyadenylation signal, aataaa, at nucleotides 
2002-2007, is in lower case letters. Restriction sites Pvu II, Eco RI, Bam HI, Xba I, and Hinc II are 
underlined. Three amino acids are enclosed in a box: Asp 70, Gly 117, and Ala 539. In atypical 
cholinesterase Asp 70 is altered to Gly 70. In the K variant Ala 539 is Thr 539. In silent cholinesterase 
Gly 117 has a frame shift mutation. 
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1987b). Figure 8 shows the 574 amino acids in each 
subunit. The active site serine, identified by alkylation 
with tritiated DFP, is serine 198. 
The cholinesterase used for sequencing was puri- 
fied from 150 L of pooled human plasma donated 
by approximately 600 random individuals. The 
amino acid sequence therefore represents the usual 
cholinesterase genotype. If a rare variant happened to 
be included in the pooled sample then the peptide 
containing the altered amino acid would have sepa- 
rated from the usual peptide on HPLC and would not 
have been sequenced because its yield would have 
been too low. The techniques of HPLC purification 
of peptides and sequencing by Edman degradation 
would, however, have revealed a polymorphism with 
a frequency of about 50% if it existed. However, no 
common polymorphism was found. 
Cholinesterase may contain one free sulfhydryl 
group at Cys 66. Tomlinson and Kinsch (1989) 
titrated one free sulfhydryl using a fluorescent 
sulfhydryl-specific reagent. However, Cys 66 did not 
react with iodoacetic acid (Lockridge et al., 1987a) 
suggesting that Cys 66 is located in a hydrophobic 
pocket. 
Amino acid composition analysis as well as 
sequence analysis gave no evidence to suggest that 
Cys 66 might be bound to a remnant of a collagen 
tail. This was a possibility because in acetylcholin- 
esterase the collagen tail is covalently attached to the 
catalytic subunit via an as yet unidentified disulfide 
bond. Torpedo acetylcholinesterase has one free 
sulfhydryl, Cys 231 (MacPhee-Quigley et al., 1986), in 
a location quite different from the free sulfhydryl, 
Cys 66, of human cholinesterase. 
3.8. DISULFIDE BONDS 
There are 8 cysteines in each subunit. Six cysteines 
form three internal disulfide loops between Cys 
65-92, 252-263, and 400-519 (Lockridge et al., 
1987a; Fig. 9). The number of amino acids in each of 
the disulfide loops is exactly the same in human 
cholinesterase and in Torpedo acetylcholinesterase 
(MacPhee-Quigley et al., 1986). 
The cysteine near the carboxyl terminal, Cys 571, 
forms a disulfide bond with Cys 571 of an identical 
subunit. This accounts for the existence of the 
170,000dalton dimer observed on SDS gel in the 
absence of reducing agent. The interchain disulfide 
bond is near the surface of the molecule and can be 
selectively reduced and alkylated (Lockridge et al., 
1979). It is also easily clipped off by proteolytic agents 
(Lockridge and La Du, 1982). The molecule remains 
a tetramer even after the interchain disulfide bond 
has been removed by proteolysis or has been selec- 
tively reduced and alkylated. One function of the 
interchain disulfide bond is to stabilize the molecule. 
This is measured by heat stability tests which 
show that intact cholinesterase has a half-life of 
54min at 55°C, whereas selectively reduced and 
alkylated cholinesterase has a half-life of 16 min at 
55°C (Lockridge et al., 1979). 
3.9. CARBOHYDRATES 
Nine carbohydrate chains are attached to aspara- 
gines at positions 17, 57, 106, 241,256, 341,455, 481, 
and 486 in each subunit (Lockridge et al., 1987b; 
Fig. 9). The number and location of carbohydrate 
chains were determined during amino acid sequenc- 
ing. Thus, the cholinesterase molecule contains 36 
carbohydrate chains per tetramer. The average carbo- 
hydrate chain terminates with 2 sialic acids. Thus, the 
cholinesterase molecule has a negative charge of 
minus 72. This large negative charge accounts for 
its low isoelectric point of approximately 4.0 (Das 
and Liddeil, 1970). Advantage of this unusually low 
pI  value is taken during purification on anion 
exchange chromatography where cholinesterase is 
one of only a few proteins that binds to DEAE resin 
at pH 4.0. 
The finding of nine carbohydrate chains per sub- 
unit is consistent with the report by Haupt et al. 
(1966) that 23.9% of the weight of human serum 
cholinesterase is due to carbohydrate. These authors 
reported a carbohydrate composition of 9.3% galac- 
tose plus mannose, 8.4% acetylhexosamine, 6.0% 
acetylneuraminic, and 0.2% fucose. This can be 
calculated to represent 50 residues of galactose plus 
mannose per subunit, 35 acetylhexosamines, 18 
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FIG. 9. Two identical subunits joined by interchain disulfide. The subunits are covalently linked through 
a disulfide bond at Cys 571. Other disulfide bonds are between Cys 65-92, 252-263, and 400-519 
(Lockridge et al., 1987a). The nine carbohydrate chains (CHO) are attached to asparagines. The active 
site serine is serine 198. The carboxyl terminus is residue 574. Carbohydrates contribute 23.9% to the 
molecular weight, which is 85,534 per glycosylated subunit. 
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acetyl~euraminic acids (sialic acid), and 1.2 residues 
of fucose per subunit. These data suggest that the 
carbohydrate chains are the complex type terminat- 
ing in sialic acid. 
With one exception, all asparagines in the 
cholinesterase sequence that could theoretically be 
attached to carbohydrate were found to be glycosy- 
lated. The single exception was asparagine 485, which 
is adjacent to the glycosylated asparagine 486. It is 
not surprising that asparagine 485 is not glycosylated 
since N-glycosidic linkages are commonly separated 
by several amino acids and do not occur on adjacent 
asparagines. 
3.10. SUBUNIT ORGANIZATION 
The majority of cholinesterase in human serum 
(approximately 95%) is a water-soluble, globular 
G4 form, having no glycolipid anchor and no colla- 
gen tail. It is a tetramer of four identical subunits 
(Lockridge et al., 1987b). There are four active sites 
per molecule (Lockridge and La Du, 1978). Figure 10 
is a schematic diagram showing the four subunits 
connected by two interchain disulfide bonds (Lock- 
ridge et al., 1979). The interchain disulfide bonds are 
not required for the tetrameric organization of the 
subunits; the molecule is a tetramer even when the 
interchain disulfide bonds are reduced and alkylated, 
or removed altogether by proteolysis (Lockridge and 
La Du, 1982). 
Strong noncovalent bonds hold the four subunits 
together. The tetramer cannot be dissociated into 
active subunits. To generate subunits having cholin- 
esterase activity one must use proteases, such as 
trypsin, or sonication. The resulting subunits have 
apparent molecular weights that are indistinguishable 
from the molecular weight of intact subunits, though 
it can be shown that a small peptide has been cleaved 
off (Lockridge and La Du, 1982). 
Approximately 5% of the cholinesterase in 
human serum consists of monomer and dimers, 
some of which may be degradation products due 
to proteolysis (Lockridge and La Du, 1982). Other 
tissues, for example muscle, contain asymmetric 
forms with a collagen-like tail, similar to the asym- 
metric forms of acetylcholinesterase (Silman and 
Futerman, 1987). 
3.11. ACTIVE SITE 
When cholinesterase is exposed to diisopropyl 
fluorophosphate (DFP), the enzyme loses all activity, 
and a single amino acid becomes alkylated. The 
alkylated amino acid is the active site serine located 
198 amino acids from the N-terminal (Lockridge 
et al., 1987b; Lockridge and La Du, 1986). To date 
only Ser 198 is known to belong to the active site. 
Other amino acids that participate in catalysis or 
substrate binding are speculated to be aspartic acid, 
histidine, tyrosine, tryptophan, arginine, and lysine 
(Boopathy and Balasubramanian, 1985). Aspartic 
acid and histidine may be part of a catalytic triad 
similar to the catalytic triad, Asp-His-Ser,  of the 
serine proteases. Tryptophan and tyrosine may be in 
the hydrophobic binding pocket (Cohen et al., 1959; 
Chan et al., 1974). 
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FIG. 10. Subunit organization of human serum cholin- 
esterase. Four identical subunits are held together by non- 
covalent bonds. The subunits are arranged as a dimer of 
dimers with each dimer containing two subunits joined by 
a single interchain disulfide bond at Cys 571. The enzyme 
remains fully active and is still a tetramer after the interchain 
disulfides have been selectively reduced and alkylated. There 
is one active site per subunit. (Lockridge et al., 1979). 
Reprinted with the permission of the copyright holder, 
The American Society for Biochemistry and Molecular 
Biology, Bethesda. 
One approach to identifying amino acids in the 
active site is to compare the amino acid sequences of 
the one cholinesterase and four acetylcholinesterases 
which have been sequenced to date (Lockridge et aL, 
1987b; Schumacher et al., 1986; Hall and Spierer, 
1986; Sikorav et al., 1987; Smyth et al., 1988), and to 
assume that residues involved in catalysis must be 
conserved. Only two histidines are conserved and 
these are His 423 and His 438 (Fig. l l). Both 
histidines may be important for catalysis. Krupka 
(1966a) found two histidines in the active center. One 
with a pK of 5.5 functioned in acetylation and was 
located at least 9 A from the anionic site, while the 
other with a pK of 6.3 functioned in deacetylation 
and was located within 5 A of the anionic site. 
4. FAMILY OF SERINE ESTERASES 
Cholinesterase activity is irreversibly inhibited by 
DFP due to alkylation of the active site serine. This 
characteristic is shared by the family of serine pro- 
teases which includes trypsin, chymotrypsin, and the 
blood coagulation factors. For  a long time it was 
speculated that the cholinesterases may belong to the 
family of serine proteases. Determination of the com- 
plete amino acid sequence of human serum cholin- 
esterase as well as of several acetylcholinesterases has 
shown that there is no significant sequence homology 
between the cholinesterases and the serine proteases. 
In addition, there is no resemblance between their 
patterns of disulfide bonds. It appears, instead, that 
the cholinesterases belong to a distinct family of 
serine esterases. Figure l l  is a schematic diagram 
of proteins that have sequence homology with 
cholinesterase and includes chymotrypsinogen for 
comparison. Besides the cholinesterases, the family 
includes a rabbit liver microsomal esterase, esterase-6 
from Drosophila, and the carboxyl terminal portion 
of thyroglobulin. There are three disulfide loops 
in the cholinesterases and in thyroglobulin and the 
loops are similarly located. Rabbit esterase and 
Drosophila esterase-6 have the first two disulfide 
loops, but not the third. The number of amino acids 
in each of the disulfide loops is similar. In contrast, 
chymotrypsinogen has 5 disulfide loops arranged in a 
pattern which is very different from the pattern in the 
cholinesterases. 
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FIG. I 1. The cholinesterase family of serine esterases is distinct from the serine protease family. This figure 
compares proteins that have sequenced homology with human cholinesterase with one member of the 
serine protease family, namely with bovine chymotrypsinogen. Boxes represent disulfide bonds. Conserved 
residues are shown. These include the active site serine, an aspartic acid that may be part of the catalytic 
triad, and histidines that may be important for catalysis. The number at the end of each line is either the 
total number of amino acids in the mature protein or the number of amino acids deduced from cDNA 
including the signal peptide. The amino acid sequence of Torpedo AChE (Schumacher et al., 1986; Sikorav 
et al., 1987) is 54% identical to the sequence of human ChE, fetal bovine AChE 50% (Smyth et al., 1988), 
Drosophila melanogaster AChE 38% (Hall and Spierer, 1986), rabbit liver microsomal esterase 30% 
(Korza and Ozols, 1988), Drosophila esterase-6 19% (Oakeshott et al., 1987), and bovine thyroglobulin 
28% (Lockridge et al., 1987b). In contrast, bovine chymotrypsinogen has no significant sequence identity. 
Parentheses are placed around Cys 256 of bovine AChE because this amino acid has not yet been 
sequenced, and its presence is implied. 
The active site serine is in position 198 in human 
cholinesterase and in a similar position in each of the 
proteins including chymotrypsinogen. Each of the 
family members has aspartic acid immediately adja- 
cent to Cys in the first disulfide loop. The amino acid 
sequence around this aspartic acid is highly con- 
served, being Se r -G lu -Asp -Cys -Leu -Tyr -Leu  in six 
proteins: human cholinesterase, acetylcholinesterase 
from Torpedo californica and marmorata, acetyl- 
cholinesterase from fetal bovine serum, liver microso- 
real esterase from rabbit, and bovine thyroglobulin. 
In Drosophila acetylcholinesterase the conserved 
amino acids are Ser- -Glu-Asp-Cys-Leu-Tyr ,  and in 
Drosophila esterase-6 they are Glu-Asp-Cys-Leu .  
We speculate that Asp 91 of human cholinesterase 
belongs to the catalytic triad, Asp/His/Ser. 
Two histidines, His 423 and His 438, are conserved 
in the proteins in Fig. I I .  Only thyroglobulin is 
missing these histidines and thyroglobulin has no 
esterase activity. We speculate that both histidines are 
important  for catalysis. These two histidines are 
absent in the serine proteases, exemplified by chymo- 
trypsinogen in Fig. 11, because none has a homolo- 
gous protein region. Instead, the serine proteases 
have histidine at position 57. Histidine 57 is missing 
in human cholinesterase and Torpedo acetylcholin- 
esterase, but seems to be conserved in Drosophila 
acetylcholinesterase, rabbit esterase, and in thyro- 
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globulin. These comparisons suggest that the cholin- 
esterases belong to a family of serine esterases that 
is structurally distinct from the family of serine 
proteases. 
5. THE USUAL CHOLINESTERASE 
GENE 
5.1. cDNA SEQUENCE 
The cDNA for human cholinesterase (Fig. 8) 
was isolated independently by two laboratories. 
Both laboratories used oligonucleotide probes to 
isolate cholinesterase clones. Prody et al. (1987) 
found one clone in a cDNA library from fetal brain 
and an overlapping clone in a library from fetal 
liver. McTiernan et al. (1987) isolated overlapping 
clones from a cDNA library prepared from a new- 
born brain. The nucleotide sequences from the two 
laboratories were nearly identical. The difference in 
developmental age of the tissues from which the 
mRNA was prepared, and the difference in tissue 
of origin, did not affect the nucleotide sequence. 
Furthermore, the coding sequence of the clones 
corresponded exactly to the known amino acid se- 
quence of adult serum cholinesterase. It can be 
concluded that cholinesterase in human embryonic, 
newborn, and adult tissues has the same amino acid 
sequence. 
5.2. 5' REGION 
There are multiple translation initiation sites in the 
5' region of the cDNA (Fig. 8). Four of these ATG 
codons are in the reading frame, and one ATG is out 
of the frame (McTiernan et al., 1987). Only the ATG 
at Met - 2 8  lies within a consensus sequence for 
initiator sites. On this basis the signal peptide most 
likely begins with Met - 2 8  and has a total length of 
28 amino acids. It is not common to have multiple 
ATGs in the 5' region and they may have some 
function, for example, in regulation of expression. 
The cDNAs for Drosophila and Torpedo acetyl- 
cholinesterase also contain multiple ATGs in the 5' 
region though they are separated by stop codons. 
(Hall and Spierer, 1986; Sikorav et al., 1987). 
5.3.3' REGION 
The 3' untranslated region contains 2 termination 
sites, cDNA clones have been isolated that terminate 
at each of these sites. One site involves the poly- 
adenylation signal, AATAAA, at nucleotides 
2002-2007 and the polyA addition site, CA, at nucle- 
otides 2025-2026. The second polyadenylation signal 
appears to be a nonconsensus signal, ATTAAA, at 
nucleotides 2182-2187. Both McTiernan et al. (1987) 
and Prody et al. (1987) isolated clones which used this 
nonconsensus signal. The presence of multiple termi- 
nation sites suggests the existence of multiple sizes of 
mRNA having the same coding potential. 
Alternative splicing to produce different mRNAs 
coding for either the asymmetric or the glycolipid 
anchored form ofacetylcholinesterase has been demon- 
strated for Torpedo acetylcholinesterase (Gibney 
et al., 1988; Sikorav et al., 1988). A similar mecha- 
nism for producing various forms of human 
cholinesterase is likely to exist. 
5.4. ONE CHOLINESTERASE GENE 
We isolated 5 genomic clones representing the gene 
for human cholinesterase (Arpagaus et al., 1990). The 
gene is approximately 80 kilobases in length and its 
coding region is divided into 4 exons. Each exon was 
subcloned into a plasmid for the purpose of having 
a set of exon-specific probes. The exon probes were 
hybridized to blots of human genomic DNA as 
shown in Fig. 12. It is immediately apparent that 
each probe yielded only one band in most digests 
and no more than two bands in other digests. This 
result is the strongest evidence we have that there 
is only one gene for cholinesterase. If two or more 
genes existed, there would be multiple bands in each 
lane because intron sequences are not conserved 
and therefore each gene would have its own set of 
restriction sites. An additional supporting argument 
from Fig. 12 is that the sizes of the restriction 
fragments are in complete agreement with the restric- 
tion map which was derived from the isolated 
genomic clones. Had there been several genes and had 
we isolated just one of the cholinesterase genes, then 
blots of total human genomic DNA would have 
yielded hybridizing fragments that did not fit the map 
constructed for one gene. No such problems were 
encountered and our results are entirely consistent 
with the interpretation that there is only one gene for 
human cholinesterase. 
Additional support is the sequence of the isolated 
genomic clones. Each exon was completely sequenced 
and found to agree with the cDNA sequence. A 
second gene would have been expected to differ from 
the cDNA sequence to some extent. 
A final supporting argument comes from the 
results of gene amplification by the polymerase 
chain reaction. In this procedure total human DNA 
is present in the tube during the amplification reac- 
tion. Therefore all cholinesterase genes are amplified 
at the same time when the priming oligonucleotides 
correspond to coding regions. If there were two 
cholinesterase genes, for example, then DNA from a 
homozygous atypical would have one atypical gene 
and one gene that was not atypical. Sequencing of 
the amplified, double-stranded DNA would have 
shown the atypical as well as the nonatypical 
sequence on one sequencing gel, that is the homo- 
zygous atypical would have looked like a hetero- 
zygote on the sequencing gel. A picture of the 
sequencing results is shown in Fig. 6 where it is 
clear that the homozygous atypical reflects one gene 
only. 
The above arguments supporting one gene are 
presented in detail because they are used to refute 
the existence of a second locus for cholinesterase. 
This affects the interpretation of C5+ ,  which had 
been thought to arise from a second cholinesterase 
locus. 
The genomic blots in Fig. 12 did not reveal the gene 
for acetylcholinesterase, which indicates that the gene 
for human acetylcholinesterase may be less than 60°/° 
identical with the gene for human cholinesterase. 
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FIG. 12. Southern blots of human genomic DNA. Genomic DNA isolated from white blood cells of a single 
donor was digested with EcoRI, PstI, Xbal, Pvull, HinclI, Hind III, and TaqI. Each lane of the agarose 
gel contained 10 #g DNA, which was transferred to nylon membrane (Genescreen, NEF-972). The blots 
were hybridized in 6 × SSC, 0.25% dry milk, at 60°C with P32-1abeled probes at a concentration of 
5 ng/ml. Blots were washed with three fluid changes in 2 x SSC, 0.1% SDS at 60°C for I hr each, and 
exposed for 16 hr with intensifying screen. Exon specific probes were prepared from genomic clones. In 
panel 1 the probe was a 0.8 kb PstI/HindllI fragment including Exon 1. In panel 2 the probe was a 2.4 kb 
EcoRI/EcoRI fragment including Exon 2. In panel 3 the probe was a 1.7kb EcoRI/XbaI fragment 
including Exon 3. In panel 4 the probe was a 0.7 kb RsaI/RsaI fragment including Exon 4. The blots show 
only one gene for human cholinesterase (Arpagaus et al., 1990). Reprinted with the permission of the 
copyright holder, the American Chemical Society, Washington, D.C. 
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5.5. LOCATION ON CHROMOSOME 3 
Human cholinesterase is on chromosome 3. This 
result was deduced from the linkage of genetic vari- 
ants of cholinesterase with transferrin, and the known 
location of transferrin on the long arm of chromo- 
some 3 in region 3q21-25 (Yang e t  al. ,  1984). The 
linkage group includes transferrin, cholinesterase, 
ceruloplasmin, and alpha2HS glycoprotein. This 
location was confirmed by Soreq e t  al. (1987) by 
hybridization experiments with cholinesterase cDNA. 
A second, weaker hybridization site was found on 
chromosome 16 by Soreq et  al. (1987), who specu- 
lated that chromosome 16 may contain the gene for 
C5+ cholinesterase. Our results do not agree with 
this interpretation as we find only one cholinesterase 
gene, 
5.6. CHOLINESTERASE IN VARIOUS TISSUES 
The cholinesterase in serum is generally considered 
to be synthesized in the liver. New supporting evi- 
dence is the isolation of a cholinesterase cDNA clone 
from a human liver library (Prody et  al. ,  1987), thus 
demonstrating that the liver must have mRNA for 
cholinesterase. A second supporting argument is 
the finding that liver transplantation into a patient 
whose cholinesterase genotype was heterozygous 
atypical-usual resulted in the circulation of cholin- 
esterase having the homozygous usual genotype 
(Khoury e t  al. ,  1987). 
The amino acid sequence deduced from the 
nucleotide sequence of cholinesterase cDNA clones 
isolated from liver (Prody e t  al. ,  1987) and brain 
(McTiernan et  al. ,  1987) was the same as the amino 
acid sequence of the protein isolated from serum 
(Lockridge et  al., 1987b). This leads to the conclusion 
that cholinesterase in three different human tissues, in 
liver, brain, and serum, is identical. 
6. ATYPICAL CHOLINESTERASE 
6.1. PURIFICATION OF ATYPICAL CHOLINESTERASE 
PROTEIN 
Three liters of plasma were collected from a 
single individual over 5 years. The plasma was stored 
at -20°C.  The first step of purification, ion 
exchange chromatography at pH4.0, worked as 
well for atypical cholinesterase as it did for usual 
cholinesterase. The second step was affinity chro- 
matography on procainamide-Sepharose. Atypical 
cholinesterase eluted at a lower salt concentration 
than usual cholinesterase from the affinity column, 
and because of this the atypical enzyme was not pure. 
A major contaminant having a subunit weight of 
45,000 could be separated on either Sephacryl S-300 
or ion exchange at pH 7 by including 50 mM dithio- 
threitol in the buffer. Our best preparation was esti- 
mated to be 84% pure. When the active site tryptic 
peptide was isolated from this preparation the pep- 
tide was not full-length and terminated in glycine 
rather than in arginine. This suggested that the 
contaminants in even our purest atypical cholin- 
esterase preparation included proteases. 
6.2. SPECIFIC ACTIVITY OF ATYPICAL CHOLINESTERASE 
At saturating substrate concentration atypical 
cholinesterase has the same activity per active site 
as usual cholinesterase (Lockridge and La Du, 
1978; Eckerson e t  al. ,  1983a). Therefore, the specific 
activity of pure atypical cholinesterase should be 
200 units/mg when activity is extrapolated to Vma x 
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condit ions.  At  0.05 mM benzoylcholine,  the concen- 
t ra t ion  for rout ine  assays, the activity of  atypical 
chol inesterase is 76% of  Vm, x, whereas the activity of  
usual cholinesterase is 97% of  Vm, x. Thus,  electro- 
phoret ical ly pure  atypical cholinesterase is expected 
to have a specific activity of  150 units/mg, measured  
with 0.05mM benzoylcholine.  The highest  specific 
activity we have ob ta ined  is 126 units/mg. 
On SDS gel e lectrophoresis  the mobil i ty  of  atypical 
cholinesterase was the same as the mobil i ty  of  usual 
cholinesterase.  Therefore,  there are no apparen t  
differences in subuni t  molecular  weight or in subuni t  
organizat ion.  In addi t ion  there are no differences 
in sialic acid content ,  heat  stability, and  immuno-  
reactivity with polyclonal  (Eckerson et al., 1983a) 
and  monoc lonca l  ant ibodies  (Brimijoin et al., 1983). 
No  physical differences between usual and  atypical 
cholinesterases could be found,  leading to the expec- 
ta t ion  tha t  a single amino  acid a l tera t ion or very 
few amino acid a l terat ions were responsible for the 
observed differences in kinetic properties.  
6.3. ATYPICAL CHOLINESTERASE MUTATION AFFECTS 
THE BINDING OF POSITIVELY CHARGED LIGANDS 
The evidence on the na ture  of  the a l tera t ion 
in atypical cholinesterase is summarized by the 
following. 
(1) The Km values for positively charged substrates  
are different for usual and  atypical cholin- 
esterase. Atypical  has a lower affinity for posi- 
tively charged substrates  (see Table 3). The K m 
values for the neutra l  substrates,  o -n i t rophenyl  
butyra te  and  a lpha-naph thy l  acetate, are the 
same for usual and  atypical cholinesterases.  This 
shows tha t  the binding site for positively charged 
substrates  has been altered in atypical cholin- 
esterase, and  that  this a l tera t ion does not  affect 
the binding of  neutral  substrates.  
(2) The binding cons tants  show that  atypical 
cholinesterase has a lower affinity for positively 
charged inhibi tors  than  does usual cholinesterase 
(see Table  4). 
(3) The mechanism of  react ion with N-methyl-(7-  
d imethylcarbamoxy)  quinol in ium iodide, a posi- 
tively charged carbamyl  ester, was found to be 
the same for atypical and  usual cholinesterase 
(Lockridge and  La Du, 1978). The rate deter- 
mining  step was decarbamylat ion.  The rate con- 
s tants  for ca rbamyla t ion  and  decarbamyla t ion  
had the same value for usual and  atypical. 
Tu rnove r  n u m b e r  also had the same value for 
usual and atypical. The only difference was in the 
affinity for substrate,  measured  as the dissocia- 
t ion constant ,  Kd. The Ko for atypical cholin- 
esterase was 5.4mM while the Kd for usual 
cholinesterase was 0.16 mM, thus confirming tha t  
atypical cholinesterase had a reduced affinity for 
the positively charged compound .  This study 
is significant because the dissociat ion constant ,  
Ko, is a more  reliable measure of  affinity than  
Km, since some reaction pa thways  can have a K m 
value that  does not  reflect affinity. 
(4) The turnover  number ,  tha t  is, moles substrate  
hydrolyzed per  minute  per  mole of  active site 
under  condi t ions  where subst ra te  is saturat ing,  is 
the same for atypical and  usual cholinesterases 
(Lockridge and  La Du, 1978; Eckerson et al., 
1983a) (see Table  3). Once the substrate  is 
bound ,  the rate of  hydrolysis is the same for 
atypical and  usual ChE. 
TABLE 4. I~ o Values for Positively Charged Inhibitors of Usual and At ff~ical 
Cholinesterase 
150 (mol/L) 
Inhibitor Usual ChE Atypical ChE 
Choline 3.0 × 10 : 5.9 x 10 -~ 
Tetramethylammonium bromide 2.8 × 10 2 7.1 x 10 2 
Meperidine 7.6 × 10 4 1.8 × 10 
Succinylcholine" 9.8 × 10 ~ 9.5 × 10 3 
Procaine '~ 4.4 × 10 5 5.9 × 10 4 
Decamethonium 1.3 x 10 ~ 1.8 x 10-3 
Chlorpromazine 4.4 x 10 6 7.4 x 10 
Dibucaine 2.7 x 10 --~ 5.4 x 10 5 
Win 5303 7.9x 10 7 2.1 × 10 5 
Monoquat analog b 3.4 × 10 7 1.7 × 10 6 
Tetracaine" 2.8 x 10 7 6.3 x 10 ~ 
Win 4510 1.5 x l0 -7 5.4 × 10 ~ 
Pancuronium bromide 1.5 x 10 v 2.2 × 10 5 
17-desoxy analog b 1.3 x 10 7 2.4 × 10 -s 
Neostigmine 1.3 x 10 7 3.3 × 10 6 
Dibutyrate analog b 1.5 × 10 -~ 4.2 × 10 6 
Physostigmine 1.4 × 10 ~ 2.7 × 10 7 
RO2-0683 1.4× 10 9 1.7x 10 7 
Win 5303 and Win 4510 are analogs of procaine. Win 5303 = 2-n- 
pentoxy. 4-amino-diethylaminoethylbenzoate hydrochloride. Win 4510 = 
2-n-hexoxy, 4-amino-diethylaminoethylthiobenzoate hydrochloride. 
RO2-0683 = dimethylcarbamate of (2-hydroxy-5-phenylbenzyl)-trimethyl- 
ammonium bromide: (a) indicates esters that serve as either substrate or 
inhibitor: (b) indicates analog of pancuronium. From data from Kalow 
and Davies (1958) and from Whittaker and Brilten (1981). Reprinted with 
the permission of the authors and the copyright holder, S. Karger, Basel. 
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(5) Atypical has no response to calcium chloride, 
whereas usual cholinesterase hydrolyzes alpha 
naphthylacetate more rapidly in the presence of 
calcium chloride (Valentino et  al., 1981). 
(6) Rates of reactivation of phosphorylated cholin- 
esterases are different, atypical being reactivated 
more rapidly than usual cholinesterase by 5 mM 
NaF (Clark et al., 1968). If  the reactivating 
species is F -  the rate of reactivation could be 
influenced by the anionic center, assuming that 
the approaching fluoride ion is repelled by the 
anionic center (Heilbronn, 1965). 
(7) Choline increases the rate of reactivation of 
phosphorylated usual cholinesterase, but has no 
effect on phosphorylated atypical cholinesterase 
(Clark et al., 1968). 
The above effects can be explained by the presence 
of an anionic site in usual cholinesterase, and the 
absence of an anionic site in atypical cholinesterase. 
The binding site for the positively charged portion of 
the choline ester substrate is called the anionic site. 
Bergmann and Wurzel (1954) suggested that the 
anionic site is a negatively charged amino acid such 
as aspartic acid or glutamic acid. The concept of an 
anionic site was challenged by Hasan et al. (1980) 
who gave evidence that the binding site in eel acetyl- 
cholinesterase fits the trimethyl group of the choline 
substrate. They claimed that size and shape are 
important, not charge. Berman and Decker (1986) 
refuted Hasan et al. (1980) by providing the interpre- 
tation that the anionic site exists at variable distances 
from the active site serine. A single nucleotide substi- 
tution has been found in atypical cholinesterase and 
this identifies the anionic site. 
6.4. LOCATION OF NUCLEOT1DE ALTERATION IN 
ATYPICAL CHOLINESTERASE 
DNA was prepared from the white cells of a person 
with atypical cholinesterase. A genomic clone con- 
taining 83% of the coding sequence was isolated and 
sequenced. A single nucleotide alteration was found 
at Asp 70, changing the codon from GAT to GGT 
(McGuire et al., 1989). This changed Asp 70 to Gly 
70 (Table 5). The DNA of nineteen additional people 
who carried the atypical cholinesterase gene was 
sequenced after amplification of cholinesterase DNA 
by polymerase chain reaction. All twenty persons 
from five families were found to have the mutation at 
Asp 70. Figure 6 shows sequencing gel results for 
usual, usual-atypical, and atypical cholinesterases 
tbr the region coding for Asp 70. 
The finding that Aspartic acid 70 has been altered 
to Glycine in atypical cholinesterase is consistent with 
the idea that a negatively charged amino acid, aspar- 
tate, is involved in binding the choline portion of 
the ester and that neutralization of this negative 
charge will significantly reduce the affinity of 
TABLE 5. Atypical Cholinesterase has 
a Mutation at Nucleotide 209 
Usual Atypical 
GAT --. GGT 
Asp 70 Gly 70 
cholinesterase for positively charged ligands. Torpedo 
acetylcholinesterase as well as fetal bovine serum 
acetylcholinesterase (Smyth et  al., 1988) contain 
aspartic acid in a homologous position. However, 
Drosophi la  acetylcholinesterase has tyrosine. This 
raises the possibility that tyrosine may participate in 
the anionic site of the Drosophi la  enzyme. 
Kieffer et al. (1986) used a photoaffinity label to 
alkylate amino acids at or near the anionic site of eel 
acetylcholinesterase. The label was found on X of the 
sequence GSXF where X may be phenylalanine 330. 
The homologous peptide in human cholinesterase is 
GTAF,  and this peptide may be located near Asp 70 
in three-dimensional structure. 
6.5. ATYPICAL CHOLINESTERASE MUTATION AFFECTS 
THE BINDING OF NEUTRAL LIGANDS 
Though the mutation in atypical cholinesterase 
primarily affects the anionic site, there is evidence 
that it also affects the hydrophobic binding site. The 
existence of a hydrophobic site was demonstrated by 
the following experiments. Chan et al. (1974) titrated 
horse serum cholinesterase which had previously 
been alkylated with DFP, with N-methylacridinium 
and found 0.95 identical, noninteracting, N-methyl- 
acridinium binding sites for each DFP binding site. 
They concluded that there was one anionic site per 
subunit. Furthermore, the tight binding constant for 
N-methylacridinium, K d = 3.8 × 10 -8 M, suggested 
the presence of a hydrophobic binding area close to 
the anionic site. 
Kabachnik et al. (1970) studied the anticholin- 
esterase potencies of  a series of 108 organophos- 
phorus inhibitors differing in the structure of their 
hydrocarbon side chains. For horse serum 
cholinesterase they concluded there were at least 2 
separate hydrophobic areas in the region of the 
anionic site: one immediately surrounding the anionic 
group (A1), and the other located outside the anionic 
site (A2) (Fig. 13). The function of the hydrophobic 
area (A I) immediately surrounding the anionic group 
is to interact with the methyl groups attached to the 
nitrogen of butyrylcholine. The A2 area accommo- 
dates a 6-carbon chain and has a spatial configura- 
tion complementary to a tertiary butyl group. Areas 
E1 and E2 are two smaller hydrophobic areas in the 
vicinity of the esteratic site; the total length of E1 and 
E2 corresponds to a 7-carbon chain of straight chain 
structure and does not fit a tertiary butyl group. 
A~ A 2 
FIG. 13. Hydrophobic areas on the active surface of 
cholinesterase. The active site serine is indicated by OH; the 
negatively charged anionic site by - .  A hydrophobic area, 
A, surrounds the anionic site, and a second hydrophobic 
area A 2 is located at some distance from the anionic site. 
Area A t is adapted to interaction with the methyl groups 
attached to the nitrogen atom of choline. Two hydrophobic 
areas, E~ and E 2 are in the vicinity of the esteratic site and 
they are complementary to a straight-chain structure having 
a total length of 7 carbons (Kabachnik et al., 1970). 
Reprinted with the permission of the authors and the 
copyright holder, Williams and Wilkins, Bethesda. 
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The hydrophobic areas close to the anionic site, AI 
and A2, may be affected by the mutation at Asp 70 
in atypical cholinesterase. This is suggested by the 
observation that alkyl alcohols, which are hydro- 
phobic and can be expected to bind to a hydrophobic 
site, have a differential effect on usual and atypical 
cholinesterase. For  example, 1% n-butyl alcohol 
elevated usual to 173% activity and depressed atypi- 
cal to 49% activity (Whittaker, 1968). Many, but not 
all homozygous atypicals have a second nucleotide 
substitution (Ala 539 ~ Thr) and this second muta- 
tion may also affect the hydrophobic areas. 
6.6. ATYPICAL CHOLINESTERASE MUTATION AFFECTS 
THE BINDING OF NEGATIVELY CHARGED LIGANDS 
The mutation in atypical cholinesterase seems to 
affect a third region of the active site. At a concen- 
tration of 0.05 mM, the negatively charged inhibitor, 
sodium fluoride, inhibits hydrolysis of benzoyl- 
choline by usual cholinesterase 60% and atypical 
cholinesterase 20% (Harris and Whittaker, 1961). 
Sodium fluoride binds to two basic groups with PKaS 
of 5.5 and 6.6 (Krupka, 1966b) and these groups may 
be His 423 and His 438. 
The ability of compounds with various charges--- 
positive, neutral, and negative charges--to differ- 
entiate usual from atypical cholinesterase can be 
explained by assuming that the active site residues are 
in close juxtaposition and are therefore all affected by 
the negative charge of aspartic acid 70. The second 
mutation (Ala 539 ~ Thr) which is present in many 
atypicals may also affect these interactions. 
TABLE 7. Silent-1 Cholinesterase has 
a Frame Shift Mutation at Nucleotide 
351 
Usual Silent 
GGT --* GGAG 
Gly 117 frame shift 
cholinesterase. A second type has 2% of normal 
activity and is recognized by cholinesterase antibod- 
ies (Rubinstein et al., 1970). Additional silent variants 
probably exist based on band patterns seen on poly- 
acrylamide gel electrophoresis stained for esterase 
activity (Altland and Goedde, 1970). 
DNA of silent cholinesterase from two sources was 
sequenced and found to have the same mutation 
at glycine 117 (McGuire et al., 1989). GGT was 
changed to G G A G  (Table 7). This frame shift muta- 
tion creates a stop codon 12 amino acids later at 
codon 129. The absence of activity in this silent 
cholinesterase is explained by the fact that the protein 
has only 128 amino acids rather than 574. The active 
site serine at position 198 is not present in this silent 
cholinesterase. The calculated molecular weight of 
the prematurely terminated silent cholinesterase is 
21,000, a value which includes the weight of three 
carbohydrate chains. One patient with this silent 
cholinesterase was a Persian female who experienced 
prolonged apnea after receiving succinylcholine. Her 
serum was tested for cholinesterase activity with 
benzoylcholine and found to have zero activity. The 
same mutation was found in a male member of an 
American-Italian family; his genotype was hetero- 
zygous for usual/silent cholinesterase. 
7. THE K VARIANT 
Many, but not all, of the atypical variants had a 
second nucleotide substitution besides the one at Asp 
70. The second substitution was at nucleotide 1615 
which changed Ala 539 (GCA) to Thr 539 (ACA) 
(McGuire et aL, 1989; Table 6). Sequencing of DNA 
from persons known to have the K variant on the 
basis of inhibition indices with R02-0683, showed 
that all K variants had the mutation at Ala 539 
(Bartels et aL, 1989) and that it could occur indepen- 
dently of the Asp 70 ~ Gly mutation. The K variant 
was named in honor of Werner Kalow by Rubinstein 
et al. (1978). 
8. SILENT CHOLINESTERASE 
8.1. LOCATION OF NUCLEOTIDE ALTERATION IN 
SILENT CHOLINESTERASE 
The silent cholinesterase phenotype includes at 
least two variants. One type has zero activity with 
butyrylthiocholine and benzoylcholine and does not 
cross-react with antiserum to normal human serum 
TABLE 6. K Variant has a Mutation at 
Nucleotide 1615 
Usual K variant 
GCA --* ACA 
Ala 539 Thr 539 
9. QUESTIONS THAT REMAIN 
UNANSWERED OR CONTROVERSIAL 
(1) What drugs should be avoided by persons who 
have a rare cholinesterase genotype? It is clear 
that succinylcholine is one such drug. Another 
candidate is mivacurium, a new muscle relaxant 
which is in the testing stage and has not yet been 
approved for human use. The local anesthetics 
procaine and chloroprocaine do not seem to 
present a clinical problem partly because of 
the way they are administered, intramuscularly 
or subcutaneously with a vasoconstrictor, and 
partly because these drugs have been replaced by 
lidocaine. What other drugs belong on this list? 
Should people with atypical cholinesterase be 
especially careful with cocaine and heroin? In 
test tube experiments atypical cholinesterase has 
a lower affinity for both drugs, but it is not 
known whether this would lead to serious conse- 
quences in vivo. For example, the question arises 
whether people who have died after a first time 
use of cocaine might have had an abnormal 
cholinesterase genotype or reduced cholin- 
esterase activity. A study underway in Toronto 
is testing cholinesterase activity in hospitalized 
cocaine users (Devenyi, 1989). 
(2) Are rare cholinesterase variants associated with 
any disease? Reports based on small numbers of 
people have turned out to be incorrect. Results 
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available to date lead to the conclusion that there 
is no link between a rare cholinesterase variant 
and any disease. Furthermore,  no cause and 
effect relationship has been found between 
changes in cholinesterase or acetylcholinesterase 
levels and nervous system disorders such as 
Alzheimers, Huntington 's ,  and brain tumors 
(Rakonczay,  1988). The Danish Cholinesterase 
Research Uni t  has approximately 7000 succinyl- 
choline-sensitive persons in its files and an exam- 
ination of  these files is in progress to search for 
possible association with a disease. 
The physiological function of  cholinesterase 
is unknown. The fact that people with zero 
cholinesterase activity (silent variant) are healthy 
and probably have a normal life-expectancy may 
suggest that cholinesterase is unimportant.  How- 
ever, an alternative explanation might be that its 
function is so important  that a backup system of 
esterases exists. High levels of  cholinesterase are 
found in embryonic tissues and a role in develop- 
ment is suspected (Layer and Sporns, 1987). 
A role in lipoprotein metabolism (Kutty et al., 
1977) also seems possible as it is known that 
cholinesterase activity is high in obesity and low 
in malnutrition. 
Questions remain about  the cholinesterase 
protein and gene. The X-ray structure has not  
yet been done. A three-dimensional understand- 
ing of  the active site structure should explain the 
tight binding of  bisquaternary inhibitors such as 
succinyldicholine and decamethonium to usual 
but not  to atypical cholinesterase. Though 
Asp 70 is part of  the anionic site, is there a 
second anionic site as well? Asp and His of  the 
catalytic triad Ser-Asp-His ,  have been tenta- 
tively identified by sequence homology. The 
cholinesterase in serum is soluble, but the 
cholinesterase in brain and muscle is membrane 
bound. To explain the synthesis of  more than 
one cholinesterase from a single gene alternative 
splicing is hypothesized, but has not  yet been 
proven. Some variants are not yet understood at 
the D N A  level, though it is anticipated that 
rapid progress will be made on the fluoride, 
H, J, and Cynthiana variants. 
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